使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Andrew P. Barnett - Head of IR
Andrew P. Barnett - Head of IR
Well, a warm welcome, everybody, to AstraZeneca's Fourth quarter and full year '23 results presentation conference call and webcast for investors and analysts. I'm Andy Barnett, Head of Investor Relations. And before I hand over to Pascal and members of the executive team, I'd like to cover some important housekeeping points.
各位大家好,熱烈歡迎參加阿斯特捷利康 2023 年第四季暨全年業績發表會的投資人與分析師電話會議及網路直播。我是投資人關係主管 Andy Barnett。在我把時間交給 Pascal 與執行團隊成員之前,我想先說明幾項重要的會議注意事項。
Firstly, as I'm probably sure you realize all the materials are already on our website for your review. Here is our forward-looking statement, which I'd encourage you to take the time to read. We'll be making comments on our performance using constant exchange rates, or CER, core financial numbers and other non-GAAP measures and non-GAAP to GAAP reconciliation is contained within the results announcement that you all have seen. All numbers quoted are in millions of U.S. dollars unless otherwise stated.
首先,如各位應該已經知道,所有資料都已上傳至我們的網站供各位查閱。這裡是我們的前瞻性陳述,建議各位撥冗閱讀。我們將以固定匯率(constant exchange rates,或 CER)、核心財務數字以及其他非 GAAP 指標來評論我們的表現;非 GAAP 與 GAAP 的調節表已包含在各位都已看到的業績公告中。除非另有說明,所有引用數字均以百萬美元為單位。
This slide shows the agenda for today's call. Following our prepared remarks, we'll open the line for questions. Of course, if you want to raise a -- ask a question in the room, you raise your hands, there'll be roving mics. For those online, please use the zoom function to raise your hand. As usual, we'll try and get through as many questions as we can through the course of the call. But if you limit the number of questions you ask it once, it will give others a fair chance to participate. And with that, Pascal, I'm going to hand over to you.
這張投影片顯示今天電話會議的議程。在我們完成事先準備的發言後,將開放提問。當然,若您想在現場提問,請舉手,現場會有工作人員持麥克風巡迴;線上與會者請使用 Zoom 的舉手功能。如同以往,我們會在會議過程中盡量回答更多問題;但若各位每次提問能控制問題數量,也能讓其他人有公平的參與機會。那麼,Pascal,我把時間交給你。
Pascal Soriot - CEO & Executive Director
Pascal Soriot - CEO & Executive Director
Thank you, Andy. Good morning, everybody, and welcome to this London Stock Exchange, where we are celebrating our 25th anniversary as a company merging us from Sweden and Zeneca from the U.K. quite a number of years ago. But I want to start my talk with this slide. And this slide is important because I want to recognize or celebrate the fact that not only it's our 25th anniversary, but importantly, we actually did achieve the goal we set ourselves 10 years ago to reach $45 billion sales in 2023. .
謝謝你,Andy。各位早安,歡迎來到倫敦證券交易所。我們今天也在此慶祝公司成立 25 週年——當年由瑞典的 Astra 與英國的 Zeneca 合併而成,距今已相當多年。不過我想用這張投影片作為開場。這張投影片很重要,因為我想肯定並慶祝的不僅是 25 週年,更重要的是,我們確實達成了 10 年前為自己設定的目標:在 2023 年達到 450 億美元的銷售額。.
And in fact, I could argue, we overachieved it because at the current exchange rates, our $20 billion -- $45 billion goal probably is closer to $40 billion. And I don't want to say just to kind of pat ourselves in the back, even though, I'd like to do this and celebrate our team's effort. But I want to mention it because we always did this with our eyes on the long-term growth. And we are embarking on another 10-year cycle. And we have announced an R&D Day because we want to refresh our strategy and show you what we are planning to do over the next 10 years. But we got this $45 billion through ups and downs, and I have to say often a lot of skepticism, but always with our eye on the long-term growth rate. And that's what we're going to do.
事實上,我甚至可以說我們超額達成,因為以目前匯率來看,我們的 200 億——450 億美元目標,可能更接近 400 億美元。我提這件事並不是只為了自我肯定,雖然我也確實想藉此慶祝團隊的努力;我之所以提到,是因為我們一直以長期成長為核心來推進這些工作。我們正要展開下一個 10 年週期,也已宣布將舉辦研發日(R&D Day),因為我們希望更新策略,並向各位展示未來 10 年的規劃。我們是在起伏與挑戰中達成 450 億美元目標的,我必須說,過程中常伴隨不少質疑,但我們始終把目光放在長期成長率上。這也是我們接下來要持續做的事。
We believe we can grow, and we believe over the next 10 years, we will deliver superior growth. And that's, of course, going to drive our profitability as a result of it. But our growth and sustainable strong growth is really what we are after.
我們相信我們能夠成長,也相信在未來 10 年我們將交出更優異的成長表現。當然,這也將進一步帶動我們的獲利能力。但我們真正追求的是成長,以及可持續的強勁成長。
And we've done this whole following the science. And again, we are embarking on a new cycle, and we are investing in new science that will shape the future of medicine and shape the future of this company, and we can talk more about this.
而我們一路走來都是「追隨科學」。同樣地,我們正邁入新的週期,並投資於將塑造醫療未來、也將塑造本公司未來的新科學;我們稍後也可以進一步談這些。
We have achieved this whole disciplined investment, even though we often have extensive debate inside the company and I know it's challenging everybody to be even more disciplined in terms of our investment. But we've constantly focused our investment on where we can deliver the most growth and also continuously focusing on oncology, cardiovascular disease, prosperity disease more recently increasing our high -- increasing our investment and keeping our eye on immune diseases and finally, rare diseases.
我們之所以能達成這些成果,靠的是一貫的紀律性投資;儘管公司內部經常有非常充分的討論,我也知道要在投資上更具紀律對每個人都是挑戰。但我們始終把投資聚焦在最能帶來成長的領域,同時持續聚焦腫瘤、心血管疾病,以及近來更著重的代謝性疾病(並提高我們的投資),同時也持續關注免疫疾病,最後還包括罕見疾病。
And the company we have today and the team we have today is very different from what it was 10 years ago. And it's really rewarding to see the progress we've made and the strengths we have developed in our portfolio, but also in the strength of the talent in the company. The way we operate in oncology today, and the same in the other TAs is very, very different. And it gives me confidence we can actually deliver another cycle of very strong growth over the next 10 years.
今天的公司與團隊,和 10 年前已大不相同。看到我們在產品組合上的進展與建立的優勢,以及公司人才實力的提升,令人非常欣慰。我們如今在腫瘤領域的運作方式——其他治療領域(TA)亦然——都與過去截然不同。這讓我有信心,我們確實能在未來 10 年再交出一個非常強勁的成長週期。
So importantly, we delivered our upgraded guidance for the year, a 15% growth, excluding COVID, we had guided to increasing to low teens. So 15% is slightly better. On the EPS front, we grew by 15%, which is also slightly better than our upgraded guidance for the year. And in the quarter 4, we saw an opportunity because we had a tax benefit. We saw an opportunity to invest to drive further growth and stronger growth next year and the years after as we are launching new products and expanding our footprint.
重要的是,我們達成了今年上調後的指引:在排除 COVID 影響下,成長 15%;我們原先指引是提升至低十位數成長,因此 15% 略優於預期。在每股盈餘(EPS)方面,我們成長 15%,也同樣略優於今年上調後的指引。至於第四季,我們因為取得稅務利益而看到一個機會;我們把握機會加大投資,以推動明年及往後年度更進一步、也更強勁的成長,因為我們正在推出新產品並擴大我們的布局。
You saw that the emerging markets out of China grew by 35%. China itself is rebounding and growing again. So China is back again on the growth trajectory and this year should be another good year. We've been improving our operating margin. You see a drop in '21, but that was -- it's a bit of an artifact because it's driven by the very large COVID sales we experienced. And of course, those were at no profit. So it dilutes our operating margin.
各位也看到,新興市場(不含中國)成長 35%。中國本身正在回升並重新成長,因此中國已回到成長軌道,今年也應該會是表現不錯的一年。我們的營業利益率也在改善。你會看到 2021 年有一個下滑,但那有點是統計上的假象,因為主要是受到我們當時非常龐大的 COVID 銷售所影響;而那些銷售當然幾乎沒有利潤,因此稀釋了我們的營業利益率。
But essentially, you can see our continuous progress. And I wanted to say today that we are committed to our goals of mid-30s by -- in the midterm. And of course, long term, will be depending on our growth opportunities and our pipeline in particular. So we are doing 3 things. As I've said before, we are driving -- we are focusing on today. We're driving growth -- top line growth and operating margin. So we deliver our financial goals and that now is 2024 really.
但整體而言,你可以看到我們持續的進展。我也想在今天重申:我們承諾在中期達成「三十多%」的目標。至於長期,則將取決於我們的成長機會,特別是我們的研發管線。因此我們正在做三件事:如我先前所說,我們聚焦當下——推動成長、推動營收(top line)成長與營業利益率,從而達成我們的財務目標;而這在現在主要就是 2024 年。
We're building the pipeline -- continuously building the pipeline so that we drive growth tomorrow, which is '25 to 2030. And we are investing in new technologies and new products to shape the future of medicine and drive long-term growth. And what I call long-term growth is what I often refer to as being the day after tomorrow, and it's '28, '29 and beyond. Ultimately, our goal is to remain a high-growth company for the next period of time, 10 years and beyond.
我們持續打造研發管線,讓我們在「明天」推動成長,也就是 2025 到 2030 年;同時我們投資新技術與新產品,以塑造醫療的未來並帶動長期成長。我所說的長期成長,常被我稱為「後天」,也就是 2028、2029 年及更往後。最終,我們的目標是在未來一段時間——10 年及更久——持續成為一家高成長公司。
You can see here that our revenue is spread across variety of therapy areas, but oncology, as you know, very well, biopharma, as you know very well and rare disease. And we had growth across all therapy areas. Oncology 21%, CVRM 18%, R&I 10%. Of course, V&I declined because we had a massive decline in COVID sales and rare disease grew by 12%, which is more than most people affected and actually more than we as expected. If you remember, we guided that we could grow by high single digit this rare disease business, but in fact, we're delivering low double-digit growth rate. And Mark will talk more about this.
你可以在這裡看到,我們的營收分布於多個治療領域,包括各位非常熟悉的腫瘤、也非常熟悉的生物製藥,以及罕見疾病。我們在所有治療領域都實現成長:腫瘤 21%、CVRM 18%、R&I 10%。當然,V&I 下滑是因為 COVID 銷售大幅下降;而罕見疾病成長 12%,高於多數人的預期,也高於我們自己的預期。若各位記得,我們原先指引罕見疾病業務可達高個位數成長,但實際上我們交出了低雙位數的成長率。Mark 會再進一步說明。
All geographies did very well, 14% in the U.S., 20% in the emerging market, which is 35% ex China and 8% in China. And you can see here the growing importance of the emerging markets outside of China. In Europe, we grew by 17% and established rest of the world, 8%. Japan is starting to be impacted by the loss of exclusivity on Nexium, of course, but still 8% growth is a pretty nice number there. So again, well diversified growth across geographies and across our disease areas.
所有地區表現都很好:美國 14%、新興市場 20%(不含中國為 35%)、中國 8%。你也可以看到,中國以外新興市場的重要性正在提升。歐洲成長 17%,已開發市場的其他地區成長 8%。日本當然開始受到 Nexium 專利到期(失去獨占性)的影響,但仍有 8% 的成長,這是相當不錯的數字。因此,再次強調,我們在地理區域與疾病領域上都呈現良好分散的成長。
So tomorrow. So this is day after -- this is today and tomorrow is really the pipeline driving the pipeline. We guided earlier this year that we had a goal of 30 new Phase III. We've achieved 27, which is short by 3 that are a little bit delayed and starting in the early '24 instead of '23, but '27 is a very large number of Phase III starts. Importantly, 10 of those have a potential to be blockbusters either new products or new indications, blockbuster, of course, being more than $1 billion. So we have 10 of these Phase III trials that if they are successful, we'll deliver $1 billion sales or more each.
接著談「明天」。也就是——這是「今天」,而「明天」主要是由研發管線所驅動、推動管線進展。我們今年稍早曾指引,目標是啟動 30 項新的第三期(Phase III)試驗。我們已完成 27 項,少了 3 項,主要是略有延遲,改在 2024 年初啟動而非 2023 年;但 27 項第三期啟動仍是非常大的數量。更重要的是,其中有 10 項具備成為重磅產品(blockbusters)的潛力——可能是新產品或新適應症;所謂重磅,當然是指年銷售額超過 10 億美元。因此,我們有 10 項第三期試驗,若成功,每一項都可帶來 10 億美元或以上的銷售額。
We also achieved 24 regulatory market -- regulatory approval across major markets. And finally, we got approval for 4 new medicines, and we are on track to deliver 15 new molecular entities, launches by 2030. And as you can see on this slide, those approvals, those new medicines range from biopharma with the Airsupra to oncology, with Truqap. Again, back to biopharm with Wainua, eplontersen and also rare diseases, Alexion with danicopan's Voydeya approval in PNH. So across the whole pipeline, we are launching new medicines.
我們也在主要市場取得了 24 項監管里程碑——獲得監管核准。最後,我們獲批 4 款新藥,並正按計畫在 2030 年前推出 15 個新分子實體(NME)。如同這張投影片所示,這些核准與新藥涵蓋從生物製藥領域的 Airsupra,到腫瘤領域的 Truqap。再回到生物製藥領域的 Wainua、eplontersen,以及罕見疾病方面,Alexion 的 danicopan 以 Voydeya 之名在 PNH 適應症獲批。因此,橫跨整個研發管線,我們正在推出新藥。
And finally, what I call the day after tomorrow is really this new technologies built new platforms. And so what are we trying to do here? First of all, we have, we believe, a tremendous opportunity to leverage our growing pipeline of antibody drug conjugates with our IO bispecifics. So in the ADC space, we started with this collaboration with Daiichi Sankyo that you know very well. We've now built our own internal portfolio of ADCs. We have 6 ADCs that are totally owned by AstraZeneca with unique targets and unique warheads. And there's more to come. We can talk about it later, but we are working on multiple targets and warheads.
最後,我所稱的「後天之後」其實就是以新技術打造的新平台。那我們在這裡想做什麼?首先,我們相信有一個巨大的機會,可以把我們日益壯大的抗體藥物複合體(ADC)研發管線,與我們的 IO 雙特異性抗體結合起來加以運用。在 ADC 領域,我們從與第一三共(Daiichi Sankyo)的合作開始,這點各位非常熟悉。如今我們已建立起自有的內部 ADC 產品組合。我們有 6 個完全由阿斯特捷利康(AstraZeneca)擁有的 ADC,具備獨特的靶點與獨特的毒載(warhead)。而且後續還會更多。我們稍後可以再談,但我們正在開發多個靶點與毒載。
And finally, and importantly, we can combine those with our bispecifics, and we have 3 of those 2 that are more advanced and are very exciting products. And we believe in oncology, this ADC combination with IO can totally transform the way cancer is treated and position us as 1 of the few companies that has the potential to leverage this combinations.
最後且同樣重要的是,我們可以把這些與我們的雙特異性抗體結合;我們目前有 3 個,其中 2 個進展更為領先,且是非常令人振奮的產品。我們相信在腫瘤領域,ADC 與 IO 的這種組合能徹底改變癌症治療方式,並使我們成為少數幾家有能力運用這些組合的公司之一。
We work on cell therapy because we believe cell therapy will be an important technology for the future. Today, those are mostly CAR-Ts in hematology. We want to take this into solid tumors, we want to take this into allogenic of the cell therapy. And we also want to take this into immune diseases, and we started working on this. So what we have been doing is leveraging our own internal efforts and our own internal technologies and combining this with putting together a series of technologies and platforms that has really the potential for us now to deliver what I was just talking about, which is moving into solid tumors, moving into allogeneic cell therapy and moving into immune diseases, and we now have a complete set of what we need. Now it's a question of integration and execution, but we have the technology that are required to achieve what our long-term goal is in cell therapy.
我們投入細胞治療,因為我們相信細胞治療將是未來的重要技術。今天,這些主要是血液腫瘤領域的 CAR-T。我們希望把它推進到實體腫瘤,也希望推進到同種異體(allogeneic)的細胞治療。我們也希望把它延伸到免疫疾病,並已開始著手。因此,我們一直在做的是:運用我們自身的內部投入與內部技術,並將其與一系列技術與平台整合,這些確實讓我們有潛力去實現我剛才談到的目標——進軍實體腫瘤、推進同種異體細胞治療、並拓展至免疫疾病;而我們現在已具備所需的完整要素。接下來就是整合與執行的問題,但我們已擁有達成細胞治療長期目標所需的技術。
And you've got listed here on Neogene, Quell, Cellectis, Gracell. And all of those together will enable us to build what we want to do in oncology and Biopharm. Another technology that we believe will shape the long-term is T cell engagers. And again, we've done that with our own internal effort and complemented with BD. The BD we do is not a random BD. It's always with a view to build a strong presence in some of the technologies we've identified, and we've done this with DC. We're doing it with cell therapy. We're doing it with T cell engagers. And finally, we do it in gene therapy with a focus on rare diseases.
你們在這裡看到列出的有 Neogene、Quell、Cellectis、Gracell。這些加在一起,將使我們能在腫瘤與生物製藥(Biopharm)領域打造我們想做的事情。另一項我們相信將塑造長期格局的技術是 T 細胞接合器(T cell engagers)。同樣地,我們透過自身內部努力來推進,並以 BD(業務發展)加以補強。我們所做的 BD 並非隨機,而是始終以在我們已識別的某些技術上建立強大布局為目的;我們在 DC 上這麼做,在細胞治療上這麼做,在 T 細胞接合器上也這麼做。最後,我們也在基因治療上這麼做,並聚焦於罕見疾病。
If you are in rare diseases, you really have to have a gene therapy approach complementing your portfolio. And of course, here, you know well, the Pfizer gene therapy portfolio acquisition and complemented with the Cellectis collaboration.
如果你在罕見疾病領域,就必須以基因治療策略來補強你的產品組合。當然,在這方面,各位也很熟悉:我們收購了輝瑞(Pfizer)的基因治療產品組合,並以與 Cellectis 的合作作為補充。
So this is really what we believe is going to drive a little bit of midterm growth with Daiichi Sankyo's collaboration in some of the ADCs, but mostly looking at driving growth, '28, '29 and beyond, so we can deliver growth today, tomorrow and the day after.
因此,這就是我們相信將在中期帶動部分成長的動能——包括與第一三共在部分 ADC 上的合作;但更重要的是著眼於推動 2028、2029 年及以後的成長,讓我們能在今天、明天,以及後天之後都交付成長。
So with this, I'll hand over to Aradhana, who's going to take you through the financials. Over to you.
接下來,我把時間交給 Aradhana,她將帶各位看財務表現。交給你了。
Aradhana Sarin - CFO & Executive Director
Aradhana Sarin - CFO & Executive Director
Thank you, Pascal. As usual, I will start with our reported P&L. As Pascal mentioned in his opening comments, total revenue increased 6% in 2023, which was at the top end of our updated guidance range. Product sales increased by 4% despite a decline of $3.8 billion in COVID-19 product sales in the year. Alliance revenue increased by 89%, driven by higher and HER2 sales in regions where Daiichi Sankyo books product sales.
謝謝你,Pascal。照例,我先從我們的列報損益表(reported P&L)開始。如 Pascal 在開場提到的,2023 年總營收成長 6%,位於我們更新後指引區間的上緣。儘管全年 COVID-19 產品銷售下滑 38 億美元,產品銷售仍成長 4%。聯盟收入(alliance revenue)成長 89%,主要受惠於在第一三共入帳產品銷售的地區,相關(higher and HER2)銷售增加所帶動。
Turning to the core P&L. Our core product sales -- sorry. Our core product sales gross margins increased by 2 percentage points to 81.7%. This step-up in gross margin was driven by lower COVID-19 revenues in 2023. In 2024, we anticipate a slightly lower product sales gross margin percentage driven by higher sales in emerging markets increased before this product supply, higher production costs in certain facilities as well as higher product sales for partnered products and regions where we book sales and then pay out a profit share to our partners through cost of sales.
接著看核心損益表(core P&L)。我們的核心產品銷售——抱歉,我們的核心產品銷售毛利率提高 2 個百分點至 81.7%。毛利率的提升主要是因為 2023 年 COVID-19 收入較低。2024 年,我們預期產品銷售毛利率百分比將略為下降,原因包括:新興市場銷售占比提高、產品供應在此之前增加、部分廠區生產成本上升,以及合作產品與我們入帳銷售的地區之產品銷售增加;此外,我們會透過銷貨成本向合作夥伴支付利潤分成。
Core operating costs increased by 9% in 2023. R&D costs increased by 9%, driven by 27 new Phase III starts in last year including multiple trials of our PD-1 CTLA-4 bispecific [more rustamic] and our oral SERD camizestrant. R&D cost as a percentage of total revenue was 22%, in line with our ambition. As expected, poor SG&A stepped up in the fourth quarter relative to the third quarter in 2023. We increased our investment in new launches behind Wainua, Truqap and Airsupra and continue to invest behind indications, expansions such as Farxiga in CKD and heart failure and Imfinzi across tumor types.
2023 年核心營運成本成長 9%。研發(R&D)成本成長 9%,主要因去年啟動了 27 項新的第三期(Phase III)試驗,其中包括我們的 PD-1/CTLA-4 雙特異性抗體([more rustamic])以及口服 SERD camizestrant 的多項試驗。研發成本占總營收比重為 22%,符合我們的目標。如預期,2023 年第四季的核心 SG&A 相較第三季有所上升。我們加大了對 Wainua、Truqap 與 Airsupra 新上市的投資,並持續投入於適應症擴展,例如 Farxiga 在 CKD 與心衰竭,以及 Imfinzi 橫跨多種腫瘤類型的拓展。
Our full year core tax rate of 17% came in slightly below our guidance. The fourth quarter tax rate benefited from an adjustment to deferred taxes following an intra-group purchase of certain intellectual property, offset by unfavorable tax ruling in certain jurisdictions. Overall, our P&L allowed us to increase investments in both R&D and SG&A in the fourth quarter. Core EPS for the full year 2023 was $7.26, a growth of 15% versus the prior year.
全年核心有效稅率為 17%,略低於我們的指引。第四季稅率受惠於因集團內購買部分智慧財產權而對遞延所得稅所做的調整,但被部分司法管轄區不利的稅務裁定所抵銷。整體而言,我們的損益表使我們能在第四季同時增加對研發與 SG&A 的投資。2023 年全年核心每股盈餘(Core EPS)為 7.26 美元,較前一年成長 15%。
As Pascal stated earlier, we have made good progress on both top and bottom line delivery in recent years, and we remain on track to deliver both industry-leading growth and improve operating margin to the mid-30s in the midterm, balanced by the need for continued investment to drive top line growth in both the near term and midterm and long term.
如 Pascal 先前所述,近年來我們在營收端與獲利端的交付都取得良好進展;我們仍按計畫在中期實現產業領先的成長,並將營業利益率提升至 30% 中段水準。同時,我們也需在近、中、長期持續投資,以推動營收成長,並在兩者之間取得平衡。
Today, we are pleased to announce our 2024 full year guidance. We anticipate our total revenue of low double-digit to low teens percentage increase and our core EPS of low double digits to low teen percentage increase as well. Collaboration revenue is expected to increase substantially driven by success-based milestones and certain anticipated transactions. Other operating income, on the other hand, is anticipated to decrease substantially.
今天,我們很高興宣布 2024 年全年指引。我們預期總營收將以低雙位數至低十位數百分比成長,核心 EPS 亦將以低雙位數至低十位數百分比成長。合作收入(collaboration revenue)預期將大幅增加,主要由成功導向的里程碑款以及若干預期交易所帶動。另一方面,其他營業收入(other operating income)預期將大幅下降。
Recall that in 2023, it included a one-off gain of around $700 million related to the renegotiated before test agreement and another $240 million related to the sale of [from the] court in the U.S. If FX rates for February to December were to remain at average rates seen in 2024 January, we anticipate a low single-digit adverse FX impact on both revenue and core EPS in 2024.
回顧 2023 年,其中包含一筆約 7 億美元的一次性收益,與重新協商的 before test 協議相關;另有 2.4 億美元與在美國出售 [from the] court 相關。若 2 月至 12 月的匯率維持在 2024 年 1 月的平均水準,我們預期 2024 年營收與核心 EPS 都將受到低個位數的不利匯率影響。
Cash flow from operating activities increased by $537 million in 2023. We continue to focus on improving our cash conversion and have already made significant progress in this area. Deal payments amounted to approximately $4 billion, of which, nearly half related to past business development payments, including milestone payments to Daiichi Sankyo.
2023 年營業活動現金流增加 5.37 億美元。我們持續聚焦於提升現金轉換率,並已在此方面取得顯著進展。交易付款(deal payments)約為 40 億美元,其中近一半與過往的業務發展付款相關,包括支付給第一三共的里程碑款。
For this year, we again anticipate about $2 billion in deal payments relating to historical transactions. CapEx in 2023 was around $1.4 billion. In 2024, we anticipate a significant step-up in CapEx potentially in the 50% range, driven by investments in new manufacturing capabilities such as API, inhaled products and cell therapy. Our net debt at the end of 2023 was $22.5 billion, and given very recent BD transactions, totaling about $2 billion, we anticipate this to remain at about the same level in 2024.
今年,我們同樣預期約 20 億美元的交易付款,與歷史交易相關。2023 年資本支出(CapEx)約為 14 億美元。2024 年,我們預期 CapEx 將顯著增加,可能達到約 50% 的增幅,主要由對新製造能力的投資所帶動,例如 API、吸入式產品與細胞治療。2023 年底我們的淨負債為 225 億美元;考量近期約 20 億美元的 BD 交易,我們預期 2024 年淨負債將大致維持在相同水準。
With this in mind, our finance expense is expected to increase given the current interest rate environment. Our net debt to adjusted EBITDA ratio is 1.6x on the last 12-month basis. Our capital allocation priorities remain unchanged with our #1 priority to reinvest in the business, both in the pipeline and behind new launches. We remain committed to keeping a strong investment-grade rating and we'll continue to pursue value-enhancing business development transactions. Towards the end of last year, we announced a license agreement with Eccogene and the proposed acquisitions of Icosavax and Gracell. Finally, we maintain our progressive dividend policy defined as either a stable or increasing dividend.
考量到這一點,在目前的利率環境下,我們的財務費用預期將增加。以過去12個月為基礎計算,我們的淨負債對調整後EBITDA比率為1.6倍。我們的資本配置優先順序維持不變,首要任務仍是再投資於業務,包括研發管線以及新產品上市後的推廣。我們仍致力於維持強健的投資級評等,並將持續尋求可提升價值的業務發展交易。去年年底,我們宣布與Eccogene簽訂授權協議,以及擬收購Icosavax與Gracell。最後,我們維持漸進式股利政策,其定義為股利維持穩定或逐步提高。
With that, I will hand over to Dave.
接下來,我把時間交給Dave。
David Fredrickson - Executive Vice-President of Oncology Business Unit
David Fredrickson - Executive Vice-President of Oncology Business Unit
Thanks, Aradhana. Really appreciate that. So oncology total revenues of $18.4 billion in the full year period grew 21% versus the prior year, and that was driven by strong global demand of our key medicines. Tagrisso global revenues grew 6% in the fourth quarter, reflecting strong double-digit growth for the U.S. and Europe.
謝謝你,Aradhana。非常感謝。腫瘤業務全年總營收為184億美元,較前一年成長21%,主要由我們關鍵藥品的全球強勁需求所帶動。Tagrisso第四季全球營收成長6%,反映美國與歐洲的強勁雙位數成長。
Performance in the quarter was partially offset by continued impact from the June 2023 mandatory price reduction in Japan, as well as expected impact from hospital ordering dynamics in China and a rebate reclassification in Australia.
本季表現部分受到日本於2023年6月實施的強制降價持續影響所抵銷,此外亦受到中國醫院採購訂單動態的預期影響,以及澳洲回扣重新分類的影響。
In the fourth quarter, Lynparza delivered 8% product sales growth and remains the leading PARP inhibitor globally despite ongoing class challenges. In the period, we recognized $245 million in regulatory milestones from Merck, following the U.S. [PROPEL] approval and BRCA-mutated prostate cancer. Imfinzi, inclusive of Imjudo grew 52% in the fourth quarter, fueled by further global demand growth in gastrointestinal tumors.
第四季,Lynparza產品銷售成長8%,儘管同類藥物仍面臨挑戰,仍維持全球領先的PARP抑制劑地位。本期間,因美國[PROPEL]核准以及BRCA突變前列腺癌適應症,我們自Merck認列2.45億美元的法規里程碑收入。Imfinzi(含Imjudo)第四季成長52%,主要受胃腸道腫瘤領域全球需求進一步成長所帶動。
In 2024, we expect continued progress with TOPAZ-1 and HIMALAYA although TOPAZ-1 demand in the U.S. will moderate as the regimen is now established as the clear standard of care. In Japan, a 25% price reduction based on sales took effect in February of this year. An additional mandatory price reduction is anticipated later this year based on recent fixed dosing approvals.
2024年,我們預期TOPAZ-1與HIMALAYA將持續取得進展,惟由於該療程現已確立為明確的照護標準,美國TOPAZ-1需求將趨於溫和。在日本,基於銷售表現的25%降價已於今年2月生效。另預期今年稍晚,將因近期固定劑量核准而出現額外的強制降價。
Calquence total revenues increased 14% in the fourth quarter, driven by continued new patient share gains across both frontline and relapsed/refractory CLL. In HER2 total revenues of $364 million in the fourth quarter increased 68% year-on-year. In the U.S. and Germany, we're very encouraged by new patient share gains in the HER2-positive setting firmly establishing in HER2 is the undisputed standard of care across HER2-positive and HER2 low metastatic breast cancer.
Calquence第四季總營收成長14%,主要受惠於在初治以及復發/難治性CLL兩個治療線別中,持續取得新病患市占提升。HER2第四季總營收為3.64億美元,年增68%。在美國與德國,我們對HER2陽性治療情境中新病患市占的提升感到非常振奮,這也穩固確立了Enhertu在HER2陽性與HER2低表現轉移性乳癌中無可爭議的照護標準地位。
In November of last year, we received approval for Truqap, our novel AKT inhibitor in the U.S. and for Imfinzi TOPAZ-1 in China. Importantly, we received a priority review designation for an HER2 and HER2-expressing tumors an adjuvant use of Tagrisso was added for the first time to the NRDL in China at no discount.
去年11月,我們在美國取得Truqap(我們創新的AKT抑制劑)核准,並在中國取得Imfinzi TOPAZ-1核准。重要的是,我們獲得了針對HER2及HER2表現腫瘤的優先審查資格;此外,Tagrisso的輔助治療用途亦首次以不降價方式納入中國NRDL。
With the exciting approval of Truqap, we have the opportunity to further extend our leadership in breast cancer, including in the hormone receptor positive landscape. And HER2 is the established standard of care in late-line HER2 low, and we look forward to the results of the DESTINY-Breast06 trial in the first half of this year and the opportunity to bring in HER2 1 line earlier and expand into HER2 ultra-low tumors. Data from the TROPION-Breast01 trial of Dato-DXd in hormone receptor positive HER2 low breast cancer was presented at ESMO last year during the presidential symposium. Discussions with health authorities and prelaunch planning activities are already well underway.
隨著Truqap令人振奮的核准,我們有機會進一步延伸在乳癌領域的領導地位,包括在荷爾蒙受體陽性的治療版圖中。而Enhertu已在晚期治療線別的HER2低表現確立為照護標準;我們期待今年上半年DESTINY-Breast06試驗結果,並把Enhertu推進到更早一線,同時擴展至HER2超低表現腫瘤。Dato-DXd在荷爾蒙受體陽性、HER2低表現乳癌的TROPION-Breast01試驗數據,已於去年ESMO總統研討會中發表。與衛生主管機關的討論及上市前規劃活動已在積極進行中。
Finally, inline with our ambition to establish a new endocrine therapy backbone, we now have several pivotal trials ongoing in the frontline for our next-generation oral SERD camizestrant, including in combination with CDK4/6 inhibitors and Truqap. Truqap is being very well received by the clinical community in the United States, and we are already seeing rapid adoption with the majority of new starts in patients with biomarker altered tumors, who have previously received a CDK4/6 inhibitor, which is consistent with our views of the addressable population. We see potential for Truqap to become the new standard of care in second line for endocrine treated patients with PIK3CA, AKT1 or PTEN altered tumors. And with that, we'll advance to the next slide, and I'll hand over to Susan to cover R&D highlights in the quarter.
最後,為了實現建立新一代內分泌治療基礎方案的願景,我們目前有多項關鍵性試驗正在一線治療中進行,評估我們的次世代口服SERD camizestrant,包括與CDK4/6抑制劑及Truqap的合併療法。Truqap在美國臨床社群中獲得非常良好的反響,我們已看到快速採用,多數新開始治療的病患為生物標記改變的腫瘤,且先前已接受CDK4/6抑制劑治療,這與我們對可觸及族群的看法一致。我們認為Truqap有潛力成為內分泌治療後、帶有PIK3CA、AKT1或PTEN改變腫瘤病患之二線治療新照護標準。接下來我們進到下一張投影片,我把時間交給Susan,說明本季研發重點。
Susan Mary Galbraith - EVP of Oncology Research & Development
Susan Mary Galbraith - EVP of Oncology Research & Development
Thank you, Dave. In December, we entered into a definitive agreement to acquire Gracell Technologies, which furthers our cell therapy ambition across oncology and autoimmune diseases. Gracell has a proprietary cell therapy manufacturing platform called FasTCAR. The FasTCAR platform has several key benefits. First, it significantly reduces the manufacturing time from between 1 and 3 weeks to 22 to 36 hours, with the opportunity to improve medium turnaround time, and also enable increased manufacturing capacity as well as predictability of CAR-T delivery.
謝謝你,Dave。12月,我們簽署了收購Gracell Technologies的最終協議,進一步推進我們在腫瘤與自體免疫疾病領域的細胞治療願景。Gracell擁有名為FasTCAR的專有細胞治療製造平台。FasTCAR平台具備數項關鍵優勢。第一,它可將製造時間由1至3週大幅縮短至22至36小時,有機會改善中位周轉時間,並提升製造產能以及CAR-T交付的可預測性。
Second, a lower dose of cells need to be manufactured for each patient, which reduces the risk of cytokine release syndrome, and that can improve the safety profile. And third, the shorter manufacturing time delivers fitter T cells, and this potentially improves the efficacy of this CAR-T. This proposed acquisition also enriches our growing pipeline of cell therapies with GC012F, a novel clinical stage dual BCMA and CD19 targeting autologous CAR-T.
第二,每位病患所需製造的細胞劑量較低,可降低細胞激素釋放症候群的風險,並可改善安全性特徵。第三,較短的製造時間可產生狀態更佳的T細胞,可能提升此CAR-T的療效。這項擬議收購也將以GC012F豐富我們持續成長的細胞治療研發管線;GC012F為一項新穎、臨床階段的雙靶點(BCMA與CD19)自體CAR-T。
Phase I data presented at the ASH meeting in December. In 22 patients with newly diagnosed high-risk multiple myeloma, the objective response rate was 100%, and we saw a minimal residual disease negativity rate between 95% and 100%, 6 to 12 months after infusion.
第一期數據已於12月ASH年會發表。在22位新診斷的高風險多發性骨髓瘤病患中,客觀反應率為100%,且在輸注後6至12個月,我們觀察到95%至100%的微小殘存病灶(MRD)陰性率。
This demonstrates the promise of this potential therapy when you move it into an earlier line setting. Safety was also favorable with only 27% of patients experiencing either grade 1 or 2 cytokine release syndrome and no grade 3 or above events. Additionally, we did not see any neurological toxicity, which can be associated with this type of therapy. With a median follow-up time of 18.8 months median PFS and median duration of response had not been reached also highlighting the durability of the response.
這顯示當把此潛在療法推進到更早治療線別時所具備的前景。安全性亦表現良好,僅27%的病患出現第1或第2級細胞激素釋放症候群,且未出現第3級或以上事件。此外,我們未觀察到任何神經毒性,而神經毒性可能與此類療法相關。在中位追蹤時間18.8個月時,中位無惡化存活期(PFS)與中位反應持續時間尚未達到,也突顯反應的持久性。
We believe that GC012F has potential applications across hematologic malignancies, including multiple myeloma and will further bolster our hematology pipeline, adding to Calquence AZD0486, our CD19 CD3 next-generation bispecific T cell engager and AZD0305, our GPRC5D targeting antibody drug conjugate.
我們相信GC012F在血液惡性腫瘤(包括多發性骨髓瘤)具有潛在應用,並將進一步強化我們的血液學研發管線,與Calquence、AZD0486(我們的CD19/CD3次世代雙特異性T細胞接合劑)以及AZD0305(我們的GPRC5D靶向抗體藥物複合體)相互補強。
We also have 2 further homegrown hematology molecules, which have just entered the clinic. A CD123 antibody drug conjugate, AZD9829 and a PRMT5 inhibitor AZD3470. We look forward to updating you on our exciting hematology pipeline over the course of this year. And with that, can you please advance to the next slide, and I'll pass over to Ruud to cover bio-pharmaceuticals performance.
我們另有2項自研的血液學分子剛進入臨床:一項CD123抗體藥物複合體AZD9829,以及一項PRMT5抑制劑AZD3470。我們期待在今年期間持續向各位更新我們令人振奮的血液學研發管線。接下來,請切換到下一張投影片,我把時間交給Ruud,說明生物製藥業務表現。
Ruud Dobber - Executive Vice-President of BioPharmaceuticals Business Unit
Ruud Dobber - Executive Vice-President of BioPharmaceuticals Business Unit
Thank you so much, Susan. Bio-pharmaceuticals delivered total revenue of $18.4 billion in 2023, driven by growth of 18% in CVRM and 10% in R&I. Key highlights for the year included Farxiga nearing $6 billion in total revenue and R&I returning to double-digit growth.
非常感謝你,Susan。生物製藥業務在2023年實現184億美元總營收,主要由CVRM成長18%以及R&I成長10%所帶動。年度重點包括Farxiga總營收接近60億美元,以及R&I重回雙位數成長。
Turning now to the fourth quarter, where within R&I, nearly half of the total revenue came from Fasenra, Tezspire, Saphnelo and Breztri. These medicines grew by a combined 40% more than offsetting the impact of Symbicort generic entry. And in V&I, Beyfortus continued to see strong demand in its first RSV season, generating $95 million of product sales and alliance revenue for AstraZeneca in the quarter. Lastly, we received our first sales related milestone payments from Sanofi totaling $27 million.
接著看第四季,在R&I中,總營收近一半來自Fasenra、Tezspire、Saphnelo與Breztri。這些藥品合計成長40%,足以抵銷Symbicort學名藥進入市場的影響。在V&I方面,Beyfortus在其首個RSV季節持續展現強勁需求,本季為AstraZeneca帶來9,500萬美元的產品銷售與聯盟收入。最後,我們也收到來自Sanofi的首筆與銷售相關的里程碑款項,合計2,700萬美元。
We have recently launched 3 innovative new medicines within biopharmaceuticals. Launches in new areas of science and medicine require us to raise awareness among patients and practitioners and often to build additional sales forces, maximizing early momentum for these launch brands is critical to delivering on their full potential. Eplontersen is an amyloidosis treatment that we are developing in partnership with Ionis. In January, it launched with the brand-new Wainua for patients with ATTR polyneuropathy, a debilitating ultra rare disease, which is generally fatal within a decade if left and treated.
我們近期在生物製藥領域推出了 3 款創新新藥。在科學與醫學新領域的上市,要求我們提升病患與醫療從業人員的認知,且往往需要建立額外的銷售團隊;在上市初期最大化這些上市品牌的動能,對於充分釋放其潛力至關重要。Eplontersen 是一項澱粉樣變性症治療藥物,我們正與 Ionis 合作開發。今年 1 月,我們以全新品牌 Wainua 上市,用於 ATTR 多發性神經病變患者;這是一種使人衰弱的超罕見疾病,若未接受治療,通常在十年內致命。
Airsupra is the first rescue medicine to reduce exacerbation and treat the underlying inflammation. And we have shown with the MANDALA trial, a 28% reduction in the risk of severe asthma exacerbations in adult patients compared to albuterol. We formally launched Airsupra last month for adult patients. And over time, we hope to see primary care physicians in the United States changed 50 years of prescribing habits. As mentioned, we are off to a strong start and are only halfway through the first RSV season that Beyfortus has been available for infants.
Airsupra 是首款可降低惡化並治療潛在發炎的急救藥物。我們在 MANDALA 試驗中顯示,與沙丁胺醇(albuterol)相比,成人患者嚴重氣喘惡化風險降低 28%。我們已於上月正式為成人患者推出 Airsupra。隨著時間推移,我們希望看到美國基層照護醫師改變長達 50 年的處方習慣。如前所述,我們開局強勁,而 Beyfortus 供嬰兒使用的第一個 RSV 季目前也才進行到一半。
Following continued strong demand and the recent approval in China, we are planning for a substantial increase in capacity in 2024. We continue to invest behind the Farxiga brands with growth being driven across the global -- across the globe by recent launches in heart failure and chronic kidney disease.
在需求持續強勁以及近期於中國獲批之後,我們正規劃於 2024 年大幅提升產能。我們持續加碼投資 Farxiga 品牌,其成長動能來自全球各地近期在心衰竭與慢性腎臟病(CKD)領域的上市。
In the coming years, we aim to continue to build on this franchise with new combination medicines in development that address unmet needs in hypertension, heart failure and CKD, and with additional enemies in our late-stage and early-stage pipeline. Our CVRM portfolio is set to expand and evolve over the mid- to long term.
未來幾年,我們的目標是透過開發中的新型複方藥物持續壯大此一產品線,這些藥物將滿足高血壓、心衰竭與 CKD 的未被滿足需求,並在我們後期與早期研發管線中加入更多新資產。我們的 CVRM 產品組合將在中長期持續擴張並演進。
We recently commenced a Phase III trials for baxdrostat in uncontrolled and resistant hypertension as well as for zibotentan, combined with dapagliflozin, addressing patients with CKD and high proteinuria. Eplontersen is also being evaluated for the treatment of ATTR cardiomyopathy, which is estimated to affect up to 0.5 million patients worldwide. Our Phase III cardio transform trial is the largest of its kinds and is powered to show a cardiovascular mortality benefit, and we are very pleased to share today that we have obtained Fast Track designation from the FDA for our cardiomyopathy regulatory file.
我們近期已啟動 baxdrostat 用於未控制與難治性高血壓的第 III 期試驗;同時也啟動 zibotentan 與 dapagliflozin 聯合用藥的第 III 期試驗,針對 CKD 且蛋白尿偏高的患者。Eplontersen 亦正評估用於治療 ATTR 心肌病變,估計全球受影響患者可達 50 萬人。我們的第 III 期 cardio transform 試驗是同類型中規模最大的研究之一,並具備顯示心血管死亡率獲益的統計效力;我們也很高興在今日分享,我們的心肌病變法規申請檔案已獲 FDA 授予快速通道(Fast Track)資格認定。
I will now hand over to Sharon to present the latest development from the biopharma pipeline.
接下來我將交棒給 Sharon,由她介紹生物製藥研發管線的最新進展。
Sharon Barr - Executive Vice-President of BioPharmaceuticals R&D
Sharon Barr - Executive Vice-President of BioPharmaceuticals R&D
Thank you so much, Ruud. I wanted to take this opportunity to highlight our current portfolio in immunology as well as provide more color on our recent business development deals focused on immune-mediated disease. In Saphnelo's, pivotal Phase III TULIP trials in systemic lucerathermatosis, we saw positive changes in cutaneous lupus. We are building on this and expanding into new indications. We have started enrolling patients in our Phase III DAISY trial of Saphnelo in patients with systemic sclerosis, a chronic disease characterized by diffuse fibrosis and vascular abnormalities in the skin, joints and internal organs, which can be fatal.
非常感謝你,Ruud。我想藉此機會強調我們目前在免疫學領域的產品組合,並就我們近期聚焦於免疫介導疾病的業務發展交易提供更多說明。在 Saphnelo 針對系統性紅斑狼瘡的關鍵性第 III 期 TULIP 試驗中,我們觀察到皮膚型狼瘡的正向變化。我們正以此為基礎並拓展至新的適應症。我們已開始在第 III 期 DAISY 試驗中招募 Saphnelo 用於系統性硬化症患者;這是一種以皮膚、關節與內臟出現瀰漫性纖維化及血管異常為特徵的慢性疾病,可能致命。
We also have plans to initiate 2 other Saphnelo Phase III trials this year in cutaneous lupus and myositis. Our recent business development deals have accelerated our ambitions in immune-mediated diseases. Emerging data from Dr. [Seth's] academic group has shown the potential for long-term relation with CAR-Ts in systemic lupus erythematosus. Part of our definitive agreement to acquire Gracell includes autologous CAR-Ts with an ongoing Phase I investigator-initiated trial with GC012S, the C19 and BCMA CAR-T in 15 Chinese patients with SLA. We look forward to sharing the Phase I data at an upcoming conference.
我們也計畫在今年啟動另外 2 項 Saphnelo 第 III 期試驗,分別針對皮膚型狼瘡與肌炎。我們近期的業務發展交易加速了我們在免疫介導疾病上的企圖心。來自 Seth 博士學術團隊的新興數據顯示,CAR-T 在系統性紅斑狼瘡中具有達成長期緩解的潛力。我們收購 Gracell 的最終協議之一部分,包含自體 CAR-T;目前正進行一項由研究者發起的第 I 期試驗,使用 GC012S(同時靶向 C19 與 BCMA 的 CAR-T)於 15 名中國 SLA 患者。我們期待在即將到來的會議上分享第 I 期數據。
Our collaboration with Quell is designed to develop multiple engineered T regulatory cell therapies, which have the potential to be transformative in type 1 diabetes and inflammatory bowel diseases. TReg cell therapies have a unique approach of modulating the immune system to reduce inflammation and prevent immune-mediated damage to tissues. Quell's innovative platform of armored TReg's could enable sustained clinical benefit.
我們與 Quell 的合作旨在開發多項工程化調節性 T 細胞(TReg)療法,這些療法在第 1 型糖尿病與發炎性腸道疾病中具有帶來變革的潛力。TReg 細胞療法採取獨特方式,透過調節免疫系統以降低發炎並防止免疫介導的組織損傷。Quell 創新的「裝甲型」TReg 平台可望帶來可持續的臨床獲益。
And finally, our collaboration with Cellectis allows us to explore the potential of an allogeneic CAR-T platform. Off-the-shelf availability from allogeneic CAR-T cells is expected to reduce the time and cost associated with manufacturing. With these innovative transformational cell therapies as well as our internal capabilities, we are building a platform for a pipeline in immune-mediated diseases with transformative potential. I will now hand over to Marc, who will cover our rare disease portfolio.
最後,我們與 Cellectis 的合作讓我們得以探索同種異體 CAR-T 平台的潛力。同種異體 CAR-T 細胞的現成(off-the-shelf)供應,預期可降低製造相關的時間與成本。結合這些創新且具變革性的細胞療法以及我們的內部能力,我們正打造一個在免疫介導疾病領域具變革潛力的研發管線平台。接下來我將交棒給 Marc,由他介紹我們的罕見疾病產品組合。
Marc Dunoyer - CEO of Alexion & Chief Strategy Officer
Marc Dunoyer - CEO of Alexion & Chief Strategy Officer
So thank you, Sharon. And for rare disease, the total revenue achieved $7.8 billion in 2023, up 12% year-over-year driven by growth in neurology indications, increased patient demand and launches in new markets. In the quarter, Ultomiris grew 38% and plus 52% for the full year, driven by neurology indication with the vast majority of growth coming from generalized mastenagravis patients were naive to branded treatments. As previously indicated, Ultomiris revenues were broadly in line with Soliris for the year. But if you look at the fourth quarter, Ultomiris revenues exceeded Soliris. .
謝謝你,Sharon。就罕見疾病而言,2023 年總營收達 78 億美元,年增 12%,主要由神經學適應症成長、患者需求增加以及新市場上市所帶動。本季 Ultomiris 成長 38%,全年成長 52%,成長動能來自神經學適應症,其中絕大多數成長來自先前未使用品牌治療的全身型重症肌無力(gMG)患者。如先前所述,Ultomiris 全年營收大致與 Soliris 相當;但若看第四季,Ultomiris 營收已超越 Soliris。.
Our conversion strategy is progressing well with the majority of patients already converted across PHN, a typical haemolytic uraemic syndrome and gMG in our major markets. We continue to launch both medicines globally and expect the C5 franchise, Soliris and Ultomiris revenues to remain sustainable and durable. Beyond complement, both Strensiq and Koselugo grew 13% and 48%, respectively, driven by continued patient demand.
我們的轉換策略進展順利,在主要市場中,PNH、非典型溶血性尿毒症候群(aHUS)與 gMG 的多數患者已完成轉換。我們持續在全球推出兩項藥物,並預期 C5 產品線(Soliris 與 Ultomiris)的營收將維持可持續且具韌性。除補體領域外,Strensiq 與 Koselugo 分別成長 13% 與 48%,主要由持續的患者需求所驅動。
I'm also delighted to announce that we have started enrolling patients in our Phase III trials for translating amyloid cardiomyopathy as well as for hypophosphatasia. ALXN2220 is a monoclonal antibody designed to deplete toxic amyloid fibrils in the heart with the potential to treat TTR cardiomyopathy in combination with standard of care stabilizes or silences.
我也很高興宣布,我們已開始在第 III 期試驗中招募患者,分別針對轉甲狀腺素蛋白(TTR)澱粉樣心肌病變以及低磷酸酶症。ALXN2220 是一種單株抗體,設計用於清除心臟中的毒性澱粉樣纖維,並有望與標準治療(穩定劑或沉默療法)合併,用於治療 TTR 心肌病變。
Our Phase III trial is recruiting a broad range of patients with moderate and severe disease. It has been designed with hard cardiovascular endpoints all-cause mortality and cardiovascular events, which are extremely important for patients and clinicians as well as for regulators and payers.
我們的第 III 期試驗正在招募涵蓋中度與重度疾病的廣泛患者族群。試驗設計採用硬性心血管終點,包括全因死亡率與心血管事件;這些終點對患者與臨床醫師,以及監管機構與支付方都極為重要。
We have begun enrollment in our Phase III program, with efzimfotasealfa, (inaudible) including 2 trials in the pediatric setting, investing both naive and switch patients as well as a larger trial in naive adults and adolescents. These trials represent a broad set of hypophosphatasia patients, including those with both skeletal and functional improvements. We believe that this product with every 2-week dosing and lower volume injections, coupled with improved manufacturing creates a significant opportunity to increase the addressable population by 3x as compared to Strensiq. We have made great progress in our late-stage pipeline with 9 Phase III programs underway and our 10th program, Ultomiris in IgAN is initiating soon.
我們已開始在第 III 期計畫中進行招募,使用 efzimfotasealfa(聽不清),包含 2 項兒科試驗,納入初治與轉換患者,以及一項更大型的初治成人與青少年試驗。這些試驗涵蓋廣泛的低磷酸酶症患者族群,包括同時具骨骼與功能改善的患者。我們相信,該產品每 2 週一次給藥與較低注射量,再加上製造改善,將帶來顯著機會,使可觸及族群相較於 Strensiq 擴大 3 倍。我們在後期研發管線方面已取得重大進展,目前有 9 個第 III 期計畫正在進行中,而第 10 個計畫(Ultomiris 用於 IgAN)也即將啟動。
With that, I'm please announce -- will get to Pascal.
接下來,我很高興宣布——將交給 Pascal。
Pascal Soriot - CEO & Executive Director
Pascal Soriot - CEO & Executive Director
Thank you, Marc. If I move to the last slide. This is really to show you that over the next few months, we have quite a number of catalysts that are going to drive us across oncology, biopharm, but also rare diseases. And you have a few here that are listed. Of course, a number are missing. We also have FLAURA2 that will deliver updated OS data in the course of 2024.
謝謝你,Marc。若我切到最後一張投影片,這主要是要向各位展示,在接下來幾個月,我們在腫瘤、 生物製藥以及罕見疾病領域都有相當多的催化劑將推動我們前進,這裡列出其中幾項;當然,還有不少未列入。我們也有 FLAURA2,將在 2024 年期間提供更新的整體存活期(OS)數據。
But some of the most important once they are going to drive the growth of several of our important products, LAURA for Tagrisso, DESTINY-Breast06 driving an HER2, TROPION-Breast02 with Dato-DXd, the WAYPOINT study, studying Tezspire and Chronic Rhinosinusitis with Nasal Polyps, and finally, EMERALD-2 Imfinzi. But there is, of course, a lot more than this.
其中一些最重要的催化劑將推動我們多項關鍵產品的成長,包括:Tagrisso 的 LAURA、推動 HER2 的 DESTINY-Breast06、使用 Dato-DXd 的 TROPION-Breast02、WAYPOINT 研究(評估 Tezspire 用於伴鼻息肉的慢性鼻竇炎),以及最後的 EMERALD-2 Imfinzi。當然,還有遠不止這些。
The other point I wanted to make in conclusion is that the midterm pipeline is actually emerging very rapidly. We have some very good data coming up out of our bispecifics portfolio, and there will be more data points communicated in the course of this year. Our ADCs will have more data also to share about our ADCs and how this pipeline is shaping up. We have an emerging metabolism portfolio that we don't talk much yet, but is actually progressing very nicely. We have a very exciting old PCSK9 that is making good progress.
我最後想補充的另一點是,中期研發管線其實正非常快速地成形。我們的雙特異性抗體產品組合即將釋出一些非常好的數據,而且今年之內還會陸續公布更多數據點。我們的 ADC 也會有更多數據可分享,說明我們的 ADC 以及這條管線的發展樣貌。我們也有一個正在成形的代謝產品組合,雖然目前談得不多,但其實進展非常順利。我們還有一個非常令人振奮的既有 PCSK9 專案,進度良好。
Baxdrostat is for hypertension is in Phase III. And finally, we have, of course, the oral GLP-1 agent, we license then and the beauty about those agents is that they can be combined. They can be combined with ADC, they come be combined between themselves. And so we have here a metabolism portfolio that is really starting to take good shape. And beyond the products as I mentioned, there's more to come, of course, in obesity but also in cardiovascular -- in heart disease and in renal disease.
Baxdrostat 用於高血壓,目前處於第三期。最後,當然還有我們授權引進的口服 GLP-1 藥物,而這些藥物的優勢在於可以進行組合治療。它們可以與 ADC 組合,也可以彼此之間組合。因此,我們在此的代謝產品組合正開始逐步成形。除了我提到的產品之外,未來當然還會有更多進展,不僅在肥胖領域,也包括心血管——心臟疾病以及腎臟疾病。
Cell therapy, we will -- this year, communicate some of the results of mid-stage studies progression. And finally, we will also be communicating information about our new DDA pipeline, and in particular, the PARP1 selective. So as you can see here, quite a lot of new data coming up, both from the Phase III pipeline but also from mid-stage pipeline that will give you a sense for what is coming up and why we believe -- why we are so excited, why we believe we can continue to drive top line growth over the next 10 years. And drive improvement in profitability as a result of this. Finally, I want to invite you all to our R&D Day. This will be in Cambridge at the DISC, our new R&D center.
細胞治療方面,我們將在今年公布一些中期研究進展的結果。最後,我們也會公布關於我們全新的 DDA 研發管線的資訊,特別是 PARP1 選擇性抑制劑。如各位所見,接下來會有相當多的新數據出爐,既包括第三期研發管線,也包括中期研發管線,讓各位了解接下來會有哪些進展,以及為什麼我們相信——為什麼我們如此興奮、為什麼我們相信未來 10 年仍能持續推動營收成長,並因此帶動獲利能力的提升。最後,我想邀請各位參加我們的研發日(R&D Day)。活動將在劍橋的 DISC 舉行,也就是我們新的研發中心。
You will see, as you -- for those of you who join us on the 21st of May, you will see this is a fantastic site, and our teams are very excited to be there, and I'm sure it will drive further momentum in our R&D productivity. The reason we do this R&D day is, as I said before, we've just completed our 10-year journey that we started in 2014. We're engaging in the next phase of our journey in the next 10 years. And we thought it's a good time to sit back and update our strategy and show you why we are so confident that the future is bright for AstraZeneca.
各位將會看到——對於 5 月 21 日加入我們的各位而言,你們會看到這是一個非常棒的場地,我們的團隊也非常期待在那裡工作,我相信這將進一步推動我們研發生產力的動能。我們之所以舉辦這次研發日,是因為如我先前所說,我們剛完成自 2014 年開始的 10 年旅程。我們正邁入下一個 10 年旅程的新階段。我們認為現在是個好時機,回顧並更新我們的策略,並向各位展示為何我們對阿斯特捷利康(AstraZeneca)的未來充滿信心、前景光明。
So with this, I'll stop here and then open the floor for questions.
那麼我就先到這裡,接著開放提問。
James Daniel Gordon - Senior Analyst
James Daniel Gordon - Senior Analyst
James Gordon from JPMorgan. I'll do just 2 questions, please. The first 1 was on revenues for this year. So the guidance, low double-digit or low teens as a revenue target, but I think bears are worried that lots of that is collaboration revenues growing and product sales slowing. So can you just say, is that fair? Do you also think that you can sustain the same sort of pace of product sales growth? Or is it really about collaboration revenues taking over from product sales. That's the first question, please.
我是摩根大通(JPMorgan)的 James Gordon。我只問兩個問題。第一個是關於今年的營收。指引是低雙位數或低十位數的營收目標,但我想空方擔心其中很大一部分來自合作收入成長,而產品銷售成長放緩。你能否說明一下,這樣的看法是否合理?你們是否也認為能維持同樣的產品銷售成長速度?還是其實是合作收入逐步取代產品銷售成為主要動能?這是第一個問題。
And then I think the second question, the other thing that some bears have said today is that the top line guidance is about the same pace as the bottom line guidance. So that would imply then that margins might be about flat. And then I've seen, I think in Slide 6, you said that the -- in the medium-term margins will get to the mid-30s. But does that mean margins will be flat this year and then have to have a big inflection in '25 and '26 to get there? So thoughts on that and whether there is going to be a lot more OpEx and how that's going to work, please?
第二個問題是,今天一些空方也提到,營收(top line)指引的成長速度大致與獲利(bottom line)指引相同。這樣就意味著利潤率可能大致持平。另外我看到你們在第 6 張投影片提到,中期利潤率將達到 30% 中段。但這是否表示今年利潤率會持平,然後必須在 2025 與 2026 年出現很大的拐點才能達到該水準?想請你談談這點,以及是否會有更多營運費用(OpEx),以及將如何運作?
Pascal Soriot - CEO & Executive Director
Pascal Soriot - CEO & Executive Director
Thank you, James. Great questions. And I know you will open the floor, I'm sure. But let me just be very categorical here. Our product sales are going to grow very strongly. So the collaboration revenue, of course, are adding to that growth. But certainly, product sales are very much on track to deliver the kind of growth that is included in the guidance range that we are communicating.
謝謝你,James。問題很好。我知道你也會開放現場提問。但我在這裡要非常明確地說:我們的產品銷售將會非常強勁地成長。合作收入當然也會為成長增添動能,但可以肯定的是,產品銷售完全在軌道上,將能實現我們所公布指引區間中所包含的成長水準。
Aradhana Sarin - CFO & Executive Director
Aradhana Sarin - CFO & Executive Director
Yes. I mean if you look at just, for example, the growth in 2023 across the franchises, right, with oncology growing 21%, rare disease, 12, 18% in CVRM. So we -- again and all of that is from current products. So we expect that that momentum to continue into the coming year. Obviously, different products have different sort of dynamics and so forth. So the growth will come in product sales from both current products as well as some of the new launches that we have, though, again, they're early in their launch trajectory.
是的。我的意思是,如果你看例如 2023 年各事業群的成長,腫瘤成長 21%,罕見疾病 12%,CVRM 成長 18%。所以——再說一次,這些成長都來自現有產品。因此我們預期這股動能會延續到明年。當然,不同產品會有不同的動態等因素,所以產品銷售的成長將同時來自現有產品以及我們的一些新上市產品,儘管它們仍處於上市初期的成長軌跡。
I think on your second question, so when we have given obviously a range on both top line and bottom line. But some of the other elements that I mentioned in my prepared remarks. One was, for example, the finance expense that we expect slightly to go up given the transactions that we did towards the end of last year and so forth and refinancing for some of the debt that we have. The second element is we obviously benefited a little bit from the tax rate last year. So that tax rate benefit will also not be there.
至於你的第二個問題,我們確實對營收與獲利都給出了區間指引。但還有一些我在事先準備的發言中提到的其他因素。第一,例如我們預期財務費用會略為上升,原因是我們在去年底完成的一些交易,以及對部分債務進行再融資等。第二個因素是,我們去年在稅率方面也略有受益,因此今年不會再有那樣的稅率利多。
So if you look at the totality of the P&L, those will also be elements and we get to the range that we have on EPS. And when you take that into account, obviously, we expect the revenue growth to, we be pretty strong, but the operating expense growth to be lagging the revenue growth. And that's what's operating leverage.
因此,如果你從損益表(P&L)的整體來看,這些也都是影響因素,並共同導向我們所給出的 EPS 區間。把這些納入考量後,我們顯然預期營收成長會相當強勁,而營運費用的成長將落後於營收成長,這就是營運槓桿。
Emily Field - Head of European Pharmaceuticals Equity Research
Emily Field - Head of European Pharmaceuticals Equity Research
Emily Field from Barclays. I have a couple of questions on oncology. The first on Dato-DXd or AVANZAR study must have enrolled pretty quickly to be having a readout in 2025. Is that what you were to be positive, would you file based on that study? I know it's designed somewhat differently to TL07 and 08? And then on HER2 for DESTINY-Breast06, how much does the inclusion of the ultra low population expand the addressable patient set? I think you've said before that HER2 low is about 50% of breast cancers. How much bigger does that get with HER2 ultra-low?
我是巴克萊(Barclays)的 Emily Field。我有幾個關於腫瘤的問題。第一個是關於 Dato-DXd 或 AVANZAR 研究,若要在 2025 年讀出結果,應該是收案非常快。是這樣嗎?如果結果為正,你們會基於該研究提出申請嗎?我知道它的設計與 TL07 和 08 有些不同。第二個是關於 DESTINY-Breast06 的 HER2,納入 ultra-low 人群會把可治療的病人族群擴大多少?我記得你們之前說 HER2 low 約占乳癌的 50%。加入 HER2 ultra-low 後會再大多少?
Pascal Soriot - CEO & Executive Director
Pascal Soriot - CEO & Executive Director
Susan?
Susan?
Susan Mary Galbraith - EVP of Oncology Research & Development
Susan Mary Galbraith - EVP of Oncology Research & Development
Yes. So for AVANZAR -- Michel, do you have it? Yes, accrual has gone very well, which just I think demonstrates the interest and the potential, not just of data Dato-DXd, but the combination in particular with Dato-DXd plus immune checkpoint inhibition. As you know, we've seen exciting data in a couple of different settings from the TROPION-Lung02 and 04 data sets as well as the BEGONIA study in triple-negative breast cancer. I think investigators are very interested in that the potential that this has to further improve the outcomes for patients with first-line non-small cell lung cancer.
是的。關於 AVANZAR——Michel,你要補充嗎?是的,收案進展非常順利,我想這也顯示出大家對 Dato-DXd 數據的興趣與潛力,不僅是 Dato-DXd 本身,尤其是 Dato-DXd 與免疫檢查點抑制劑的組合。如各位所知,我們已在幾個不同情境中看到令人振奮的數據,包括 TROPION-Lung02 與 04 的數據集,以及三陰性乳癌的 BEGONIA 研究。我認為研究者對其潛力非常感興趣,因為它有望進一步改善一線非小細胞肺癌患者的治療結果。
Pascal Soriot - CEO & Executive Director
Pascal Soriot - CEO & Executive Director
The study is progressing very quickly in recruitment, as you pointed out. The second 1 is DB06 and the low maybe for you, Dave?
如你所指出,該研究在招募上進展非常快。第二個是 DB06,以及 low 的部分也許交給你,Dave?
David Fredrickson - Executive Vice-President of Oncology Business Unit
David Fredrickson - Executive Vice-President of Oncology Business Unit
Yes. So Thanks, Emily, for the question on that. So I think as we -- 2 things that I think are important about DB06. The first 1 is, is that it expands the opportunity if it's positive, like you highlighted to move into the ultra low specifically on that question, just to lay this out. So if we look at hormone receptor positive metastatic breast cancer, within the 60% are the IHC 1+ and 2+. So that's the HER2 low that's covered by DB04. Then we've got 25% that we estimate that's in this 0 to 1 category. So that's how much it adds within this. And then you've got about 15% that are the true zeros.
好的。Emily,謝謝你問這個問題。我想關於 DB06,有兩點很重要。第一,如果結果為正,如你所強調的,它會擴大機會,特別是可延伸到 ultra-low。就這個問題我先把架構說清楚:如果我們看荷爾蒙受體陽性的轉移性乳癌,在其中的 60% 屬於 IHC 1+ 和 2+。這就是 DB04 所涵蓋的 HER2 low。接著我們估計有 25% 落在 0 到 1 的這個區間。這就是在此族群中新增的比例。然後大約還有 15% 是真正的 0。
So first is that expansion outside of the 1+s into the ultra lows, and then also it's moving a line earlier. And so by moving the line earlier, there's 2 opportunities to see growth, and it will be data dependent, but 1 of those is, of course, a longer duration of therapy you'd hope to get as you move earlier.
所以第一是從 1+ 之外擴展到 ultra-low;第二是把治療線別往前移。當線別往前移時,就有兩個成長機會,當然會取決於數據,其中之一是——隨著治療前移,你會希望能獲得更長的治療持續時間。
The other is, is that if the data are really compelling, you could see that, that puts some pressure on what we see as a lot of endocrine recycling that takes place within these patients. So again, that will be data dependent. We'll have to see what the magnitude of benefit is. But there's 3 different opportunities for 06 to contribute to growth moving forward.
另一點是,如果數據真的非常有說服力,你可能會看到,這會對我們所看到的、在這些患者體內發生的大量內分泌再循環造成一些壓力。所以同樣地,這將取決於數據。我們必須看看效益的幅度有多大。但往後看,06 有 3 個不同的機會可以為成長做出貢獻。
Matthew Weston - Former MD and Co-Head of European Pharmaceutical Equity Research
Matthew Weston - Former MD and Co-Head of European Pharmaceutical Equity Research
It's Matthew Weston from UBS. 2 Questions. And if the first 1 I can stick with in HER2 as well. I think 4Q U.S. sales probably were a little bit light in terms of growth of what people were expecting when Daiichi reported them. So total end-user sales. And at the time, I think Daiichi commented that penetration was reaching plateau in some of the U.S. markets, but with the data expansion coming, there was going to be much more opportunity. .
我是 UBS 的 Matthew Weston。有兩個問題。第一個我想也先聚焦在 HER2。我認為第 4 季美國銷售在成長方面可能比大家在第一三共(Daiichi)公布時的預期稍微弱一些,也就是總終端用戶銷售。當時我記得第一三共提到,在美國部分市場的滲透率已接近平台期,但隨著數據擴展,將會有更多機會。.
I think a lot of investors felt that HER2 low was significantly bigger than suggesting it [already] plateaued. So I'd love to understand what's happening there. But also, Dave, if you can touch on HER2 PAM tumor. It seems to fly under the radar, may will actually be quite a significant indication.
我想很多投資人覺得 HER2 low 的市場規模明顯更大,不太像是已經[已經]進入平台期的樣子。所以我很想了解那邊到底發生了什麼。另外,Dave,如果你能談談 HER2 PAM 腫瘤。它似乎比較少被注意到,但其實可能會是一個相當重要的適應症。
And then if I rather on the second question, you added into guidance that there's essentially pointing to a onetime asset sale being something to take into account for 2024. I don't remember you're doing that for quite some time, suggesting it might be of a significant size. Is there any way you can help frame it?
然後第二個問題,你們在指引中加入了內容,基本上指出 2024 年需要把一次性的資產出售納入考量。我不記得你們有一段時間這麼做過,這似乎暗示規模可能相當可觀。你能否協助我們界定一下?
Pascal Soriot - CEO & Executive Director
Pascal Soriot - CEO & Executive Director
You want to start?
你要先開始嗎?
David Fredrickson - Executive Vice-President of Oncology Business Unit
David Fredrickson - Executive Vice-President of Oncology Business Unit
Matthew, on in HER2, and I made this comment in my prepared remarks, and I think that it's an important piece, which is I had been commenting in quarters past that we had found, that we had hit a 50% really kind of threshold that we were running into in both HER2-positive and HER2 low. But that we knew that there was opportunity to drive continued growth beyond that. And I was really pleased to see, and we've been really pleased to see that we've been putting more effort against our promotional efforts within the U.S. and large markets within Europe.
Matthew,關於 HER2,我在事先準備的發言中提到過,我認為這是一個重要的點:我在過去幾個季度一直評論,我們發現無論在 HER2 陽性或 HER2 low,都碰到了一個大約 50% 的門檻。但我們也知道仍有機會推動超過這個門檻的持續成長。我很高興看到,而且我們也一直很高興看到,我們在美國以及歐洲主要市場加大了推廣投入。
We've done that in conjunction with the Truqap launch to really make sure that we've got the promotional muscle that we need out there, and we're seeing movement in the HER2-positive new patient starts. And so that's moving in the right direction and going the right level. Now if you think about where we were, basically, Matthew, what I think happened was we had replaced a lot, if not almost all of the Kadcyla use.
我們也配合 Truqap 的上市一起做,確保我們具備所需的推廣火力,而我們也看到 HER2 陽性的新患者起始治療人數正在變動。因此方向是對的,也達到應有的水準。現在回想我們當時的狀況,基本上,Matthew,我認為發生的是我們已經取代了大量、甚至幾乎全部的 Kadcyla 使用。
And now we're moving into some harder yards, but we're getting traction against it. We turn to HER2 low, HER2-low is again an opportunity for continued growth beyond where we've gotten to. It is, in many respects, a more complicated discussion to be able to have because we're talking about multiple therapeutic alternatives that exist within the hormone receptor positive space. We're obviously working on testing efforts.
而現在我們進入了更難攻克的區域,但我們正在取得進展。再看 HER2 low,HER2-low 同樣是在目前基礎之上持續成長的機會。在很多方面,這是一個更複雜的討論,因為我們談的是在荷爾蒙受體陽性領域存在多種治療替代方案。我們也正在推動檢測相關工作。
All of this, though, I think that again, I've got optimism that we've got an opportunity to continue to grow. I think that in HER2 has a lot of growth in front of it with 03 and 04 still in the U.S., still in Europe, and I think that 06, which Emily just asked about, would be further tailwinds to add to that.
不過我認為,整體而言,我仍然樂觀,覺得我們有機會持續成長。我認為 HER2 前方仍有很大的成長空間,因為 03 和 04 在美國仍在推進、在歐洲也仍在推進;而我認為 Emily 剛剛問到的 06,將會帶來進一步的順風,為此再加一把力。
Matthew Weston - Former MD and Co-Head of European Pharmaceutical Equity Research
Matthew Weston - Former MD and Co-Head of European Pharmaceutical Equity Research
PAM tumor?
PAM 腫瘤?
David Fredrickson - Executive Vice-President of Oncology Business Unit
David Fredrickson - Executive Vice-President of Oncology Business Unit
PAM tumor. PAM tumor is a spot where right now, we've got breakthrough therapy designation in later lines in the highest of over expressors. And so I think that when you take a look at that population, you've got several thousands of patients across multiple tumor types that could be addressable for this. And while our early label might be relatively modest compared to, for example, the 03 and 04 opportunities. I think that the more evidence generation that takes place, the more that we continue to do work in this space. And if we can demonstrate in the lower levels of expression, I think PAM tumor is exactly that third leg of the stool that Susan and I were talking about to add to HER2-positive breast and HER2 low to be a good growth driver in the midterm for in HER2.
PAM 腫瘤。PAM 腫瘤目前在後線治療、且屬於最高表達者族群中,我們已獲得突破性療法認定(breakthrough therapy designation)。因此當你看這個族群時,跨多種腫瘤類型,可能有數千名患者可作為可治療對象。雖然我們早期的標籤(適應症)相較於例如 03 和 04 的機會,可能相對有限,但我認為證據生成越多、我們在這個領域持續投入越多工作,而且如果我們能在較低表達水準中證明效果,我認為 PAM 腫瘤正是 Susan 和我所談到的「三腳凳」的第三隻腳,可與 HER2 陽性乳癌以及 HER2 low 一起,成為 in HER2 在中期的良好成長驅動力。
Pascal Soriot - CEO & Executive Director
Pascal Soriot - CEO & Executive Director
So before Aradhana, do you want to take up...
所以在 Aradhana 之前,你要不要接著談……
Aradhana Sarin - CFO & Executive Director
Aradhana Sarin - CFO & Executive Director
Yes, Matthew. So we talked about the other income, which we expect to decline substantially. And again, last year, remember, there were 2 particular transactions that contributed a large amount. So we've not signaled any asset sales. We do expect collaboration revenue to increase substantially. And we've talked about milestones and potential transactions we're contemplating, but we're not in a position to give more details today, and we'll see how the year unfolds.
好的,Matthew。我們談過其他收入(other income),我們預期它會大幅下降。再提醒一次,去年有兩筆特定交易貢獻了很大的金額。所以我們並沒有釋出任何資產出售的訊號。我們確實預期合作收入(collaboration revenue)會大幅增加。我們也談到里程碑款以及我們正在考慮的潛在交易,但今天我們還無法提供更多細節,接下來就看今年的進展情況。
David Fredrickson - Executive Vice-President of Oncology Business Unit
David Fredrickson - Executive Vice-President of Oncology Business Unit
Pascal, super briefly, 1 thing that I forgot to mention on this. NCCN guidelines have included now endometrial, cervical and ovarian for and HER2 within the population that we got the priority review for. So I do think that, that's an acknowledgment that the clinical community is seeing the benefit of that study.
Pascal,補充一點我剛剛忘了提:NCCN 指南現在已將子宮內膜癌、子宮頸癌與卵巢癌納入 in HER2 的範圍,而這些也在我們獲得優先審查(priority review)的族群之內。所以我確實認為,這是在肯定臨床社群看到了該研究的效益。
Andrew Simon Baum - Global Head of Healthcare Research and MD
Andrew Simon Baum - Global Head of Healthcare Research and MD
It's Andrew Baum with Citi. Staying with in HER2. And PAM tumor trial. So you have HER2 low as part of that trial, and there's been very clear signals and many malignancies that HER2 is active.
我是 Citi 的 Andrew Baum。繼續談 in HER2,以及 PAM 腫瘤試驗。該試驗中包含 HER2 low,而且在許多惡性腫瘤中已經有非常明確的訊號顯示 HER2 具有活性。
And obviously, you have the manufacturing, it's been derisked. So my question is, are you leaving money on the table by not seeking to expedite development for individual HER2 low indications because it looks like you're not going to get approval for PAM tumor in HER2 low? So you're going to need to set trials. There are competitors with HER2 assets, we've initiated trials in those HER2-low settings. So have you just left white space for a competitor to come in when you've got an asset that you could be monetizing in that setting?
而且顯然你們的製造端已經去風險化(derisked)。所以我的問題是:你們是否因為沒有針對單一 HER2 low 適應症加速開發,而把錢留在桌上?因為看起來你們不會在 HER2 low 取得 PAM 腫瘤的核准,所以你們將需要另行設計試驗。有競爭對手也有 HER2 資產,已在那些 HER2-low 的情境中啟動試驗。所以你們是否在一個你們其實可以在該情境中變現(monetizing)的資產上,留出了空白地帶讓競爭者切入?
And then the second question is in relation to Truqap. I'm curious what you think of the enabolosib data? And how that's going to impact the use of Truqap, given you're hitting the same PI3K-AKT pathway?
第二個問題與 Truqap 有關。我想知道你怎麼看 enabolosib 的數據?鑑於你們打的是同一條 PI3K-AKT 路徑,這會如何影響 Truqap 的使用?
Pascal Soriot - CEO & Executive Director
Pascal Soriot - CEO & Executive Director
Susan?
Susan?
Susan Mary Galbraith - EVP of Oncology Research & Development
Susan Mary Galbraith - EVP of Oncology Research & Development
Yes. So for the white space question, when you got a brand like in HER2, which has really exceptional activity across. I think the philosophy is to make sure that we develop it to the maximum of its potential. So again, not everything that we're planning to do is currently visible, but you'd expect to see other trials. So I do think that we can build on what we've actually seen with PAM tumor, and I think it creates a lot of opportunity there. So we intend to leave this little white space as possible.
好的。關於空白地帶(white space)這個問題,當你擁有像 in HER2 這樣在多個領域都展現出非常卓越活性的品牌時,我認為我們的理念是確保把它開發到其最大潛力。因此,我們規劃要做的事情並非全部都已經對外可見,但你可以預期會看到其他試驗。我確實認為,我們可以在 PAM 腫瘤所看到的基礎上再往上建立,而這也創造了很多機會。所以我們的意圖是盡可能少留下這種空白地帶。
Pascal Soriot - CEO & Executive Director
Pascal Soriot - CEO & Executive Director
And in terms of the...
至於……
Susan Mary Galbraith - EVP of Oncology Research & Development
Susan Mary Galbraith - EVP of Oncology Research & Development
You want to address the market size for this.
你要談一下這個的市場規模嗎?
David Fredrickson - Executive Vice-President of Oncology Business Unit
David Fredrickson - Executive Vice-President of Oncology Business Unit
Yes, sure. I mean look, I think that what I would comment on most, Andrew, is that we're seeing very positive receptivity to Truqap. We've seen strong uptake in terms of number of new patients that are being started on therapy. We're actually hearing an awful lot of desire among the community to have seen a broader label based upon the data sets that were presented and what we've seen. And obviously, within the context of the competitive landscape, the Truqap data will ultimately be looked at within that context, but I think it really is showing favorably within that context. And we anticipate that we'll continue to have a strong launch for the medicine through the year and look forward to the additional life cycle readouts that we're going to have on the heels of, obviously, the 291.
好的,當然。我的意思是,Andrew,我最想評論的是:我們看到社群對 Truqap 的接受度非常正面。我們看到在開始治療的新患者數量方面有強勁的採用(uptake)。我們也聽到社群非常希望基於已呈現的數據集以及我們所看到的結果,能有更廣的標籤(適應症)。而且顯然在競爭格局的脈絡下,Truqap 的數據最終會在那個脈絡中被檢視,但我認為它在那個脈絡下的表現確實相當有利。我們預期今年這款藥的上市推進會持續強勁,也期待在顯然是 291 之後,我們將陸續取得更多生命週期(life cycle)的讀出結果。
Susan Mary Galbraith - EVP of Oncology Research & Development
Susan Mary Galbraith - EVP of Oncology Research & Development
So again, there are other opportunities, I would just say with capivasertib for combination, but also remember that it treats a broader group of patients than just the PI3 kinase of a mutant group. You've got [P term] and you've got the AKT activation as well. So there's multiple ways in which it is different. But I think that the first-line space is also something that is of interest.
再說一次,我會說 capivasertib 還有其他機會,例如用於聯合治療;但也請記得,它治療的患者族群比僅限於 PI3 激酶突變族群更廣。你有 [P term],也有 AKT 活化。因此它在多個面向上都不同。不過我認為,一線治療領域也是一個值得關注的方向。
David Fredrickson - Executive Vice-President of Oncology Business Unit
David Fredrickson - Executive Vice-President of Oncology Business Unit
Andrew, I mean, I think that the pace on this and maybe I skipped over because I thought it was kind of without saying, but Truqap is post CDK4/6 and the [invos] is not. So we are looking at different populations and different spots.
Andrew,我的意思是,我認為這件事的節奏——也許我略過了,因為我覺得這有點不言自明——但 Truqap 是在 CDK4/6 之後(post CDK4/6),而 [invos] 不是。所以我們看的是不同族群、不同切入點。
Susan Mary Galbraith - EVP of Oncology Research & Development
Susan Mary Galbraith - EVP of Oncology Research & Development
It is a different population. So they're taking into that first-line setting, fast progresses. So it's not -- even if you take the same population that went into 291 and look at them in the first line, they don't completely overlap with the [anabolism] patient population. I hope that's clear.
這是不同的族群。所以他們把它帶到一線治療的情境,是快速進展的患者。因此這並不是——即便你把進入 291 的同一族群拿來看一線治療,他們也不會與 [anabolism] 的患者族群完全重疊。我希望這點很清楚。
Peter James Welford - Senior Equity Analyst & European Pharmaceuticals Analyst
Peter James Welford - Senior Equity Analyst & European Pharmaceuticals Analyst
It's Peter Welford with Jefferies. Two questions sticking to the norm. So first question is on the investor event on the 21st of May. I think it was called after it's an R&D event. I guess curious, can you outline, is this going to be a event very much focused on the midterm pipeline? Or will you also be giving that 10-year vision?
我是 Jefferies 的 Peter Welford。兩個問題,照慣例。第一個問題是關於 5 月 21 日的投資人活動。我想它是在之後被稱為一個研發(R&D)活動。我想請問,你們能否概述一下:這會是一個非常聚焦於中期產品線(midterm pipeline)的活動嗎?還是你們也會提供那個 10 年願景?
And on that, is this going to be a 10-year vision setting another 10-year revenue aim? And I guess, what sort of granularity should we anticipate when we look forward to how you're going to set the aim for the next period?
另外,這是否會是在 10 年願景的框架下,再設定另一個 10 年的營收目標?我想問的是,當我們展望你們將如何為下一個期間設定目標時,我們應該預期到什麼程度的細緻度(granularity)?
And then the second one is on Airsupra. So you mentioned obviously that the 2023 was very much a year of building access, building awareness, building this. I guess curious now in 2024, you -- the comment made, I think, was over time, we expect U.S. PCPs to change 50 years of habit. I mean that sounds there's still a lot of slog to go. So you just talk about how [the paid] discussions gone? Was that successful? Is the barrier now the doctors? Or should 2024 be a year where we got anything in the model? Or is this another year where we should be really thinking about the inflections yet to come?
第二個問題是關於 Airsupra。你們提到很明顯 2023 年主要是在建立可及性(access)、建立認知(awareness)等等。我想請問,到了 2024 年,你們——我記得你們的評論是,隨著時間推移,我們預期美國基層照護醫師(PCPs)會改變 50 年的用藥習慣。我的意思是,聽起來還有很多硬仗要打。所以你能談談 [the paid] 的討論進展如何嗎?那是成功的嗎?現在的障礙是在醫師端嗎?或者 2024 年應該是我們在模型裡可以放進一些東西的一年?還是這又是我們應該把重點放在尚未到來的拐點(inflections)的一年?
Pascal Soriot - CEO & Executive Director
Pascal Soriot - CEO & Executive Director
So 2 great questions, Peter. Let me just cover the first 1 and Ruud, you could cover Airsupra. So the R&D Day, really what we want to do, as I explained earlier is, explained what our strategy is and why we think we can grow strongly over the next 10 years.
Peter,兩個都很棒的問題。我先回答第一個,Ruud 你可以回答 Airsupra。關於研發日(R&D Day),我們真正想做的,如我先前解釋的,是說明我們的策略是什麼,以及為什麼我們認為未來 10 年我們可以強勁成長。
So we are, of course, going to look at our midterm pipeline, but also we want to look at the investments we're making in new technologies, new platforms, that will actually deliver growth from '28, '29 and beyond. So we actually give you a good understanding of not only the near term but also the midterm and the long term. As it relates to whether we're going to set up a long-term revenue ambition we may, but we haven't decided this.
所以我們當然會檢視我們的中期產品線,但同時我們也想談談我們在新技術、新平台上的投資,這些投資實際上將在 2028、2029 年及之後帶來成長。因此我們會讓你對不僅是短期,也包括中期與長期有很好的理解。至於是否會設定長期營收企圖(long-term revenue ambition),我們可能會,但目前尚未決定。
But I can tell you that we are very, very confident that we can actually grow very strongly over the next few years and work through some of the issues that have been mentioned by some, for instance, Medicare (inaudible) reform, we can work through that. In the end, the impact of this is there, but it's relatively limited. I hesitate to use the word marginal, but it's quite limited in the context of our global sales. So we can walk through this. We can walk through the patent expiries that we have that are limited and continue to deliver very strong growth.
但我可以告訴你,我們非常、非常有信心,未來幾年我們確實可以非常強勁地成長,並且處理一些有人提到的議題,例如 Medicare(聽不清)改革,我們可以應對。最終,這確實會有影響,但相對有限。我不太想用「邊際」(marginal)這個詞,但在我們全球銷售的脈絡下,它相當有限。所以我們可以帶大家走過這些。我們也可以帶大家走過我們面臨的專利到期(patent expiries),其影響有限,並且持續交出非常強勁的成長。
And of course, it's not going to be the same gross number every year. But if you look at it over the next 5 years and then 10 years, we certainly can grow, and that's what we actually want to hopefully convince you as we share our strategy and we'll see whether we come up with a number or not. Go on.
當然,每年的成長絕對值不會都一樣。但如果你看未來 5 年、再看 10 年,我們確實能成長,而這正是我們希望在分享策略時能說服各位的——至於我們是否會提出一個數字,我們再看看。繼續。
Ruud Dobber - Executive Vice-President of BioPharmaceuticals Business Unit
Ruud Dobber - Executive Vice-President of BioPharmaceuticals Business Unit
Yes. Let me first rearticulate, let's say, the excitement we have regarding Airsupra. First of all, this is a very substantial market. Its in the United States alone, there are roughly 15 million to 18 million scripts only for submitral in the asthma 18 plus indication. Having said that, we started our journeys in order to gain access last year. So the good news is, we have now formulary listings in 3 of the largest commercial PBMs. Based on the registration, we were just too late in order to get Part D. So we are bidding for Part D in the course of 2024. So hopefully, that will create more access moving forward. Many patients anyway are in commercial are younger patients. What we have seen in the first few weeks, it's still very early days, is a very nice number of trialists already thousands of GPs, but also specialists are prescribing as Airsupra.
是的。讓我先再次闡述一下我們對 Airsupra 的興奮。首先,這是一個非常可觀的市場。僅在美國,在氣喘 18 歲以上適應症中,僅 submitral 的處方量大約就有 1,500 萬到 1,800 萬張。話雖如此,我們去年開始推動取得可及性(access)的工作。好消息是,我們現在已在三家最大的商業 PBM(藥品福利管理機構)的處方集(formulary)中取得收載。由於註冊時點的關係,我們在納入 Part D 上稍微晚了一步。因此我們會在 2024 年期間競標 Part D。希望這能在未來帶來更多可及性。無論如何,許多患者是在商業保險中、也較年輕。我們在最初幾週看到的——雖然仍是非常早期——是相當不錯的試用者數量,已經有數千名全科醫師(GPs),以及專科醫師在開立 Airsupra。
Having said that, access is still, let's say, an issue we are working through. So we need to buy down the course, the scripts, the course per scripts quite substantially. So my clear stay is we are off of a very strong start in the United States. But equally, of course, it will take time to get enough access in order to switch off the now conversion and hence, then the sales will follow. And it's more or less the pattern we have seen with Breztri. You've seen in the announcement, Breztri is growing over 70%. It's on its way to become a blockbuster hopefully very soon. And I think we are expecting the same pattern also for Airsupra moving forward.
話雖如此,可及性仍然——可以說——是我們正在努力解決的問題。因此我們需要大幅降低成本、處方(scripts)的成本、每張處方的成本(course per scripts)相當多。所以我明確要說的是:我們在美國的起步非常強勁。但同樣地,當然也需要時間,才能取得足夠的可及性來推動目前的轉換(conversion),進而帶動銷售。這大致上就是我們在 Breztri 身上看到的模式。你們在公告中也看到,Breztri 成長超過 70%。它正朝著希望很快成為重磅產品(blockbuster)的方向前進。我認為我們也預期 Airsupra 未來會呈現相同的模式。
Pascal Soriot - CEO & Executive Director
Pascal Soriot - CEO & Executive Director
I think really the important point, as Ruud said, is really to expect that this is not an oncology new indication that really addresses a big unmet need with a very fast sales ramp up. It's more progressive. But the beauty of this kind of inhaled products is that when you are established, you have a very durable asset. I mean look at Symbicort, it's been around for a long, long time. And it's still out there and it's still a very good product with good sales, very good profitability.
我想真正重要的一點,如 Ruud 所說,是要預期這不是一個腫瘤科的新適應症——那種能解決重大未被滿足需求、銷售快速爬坡的產品。這會更循序漸進。但這類吸入型產品的優點在於,一旦建立起來,它就是非常耐久的資產。看看 Symbicort,它已經存在很久很久了。它仍在市場上,仍然是非常好的產品,銷售良好、獲利能力也非常好。
So we have to have the resilience to get it to the right level, and then it will stay at a good level for a long time to come because there's not a huge amount of competition, and there is a clear unmet need there.
所以我們必須有韌性把它推到正確的水準,然後它會在很長一段時間內維持在良好水準,因為競爭並不算非常激烈,而且那裡確實存在明確的未被滿足需求。
Mark Douglas Purcell - Equity Analyst
Mark Douglas Purcell - Equity Analyst
It's Mark Purcell from Morgan Stanley. Two questions. The first one for Aradhana. I guess what some people have been concerned by this morning is the certain anticipated transactions part of your CR guidance, which you expect to increase substantially in 2024. I guess they're triangulate that with a Part 1 selected moving forward.
我是 Morgan Stanley 的 Mark Purcell。兩個問題。第一個給 Aradhana。我想今天早上有些人擔心的是,你們 CR 指引中的某些預期交易部分,你們預期在 2024 年會大幅增加。我想他們會把這點與未來的 Part 1 selected 進行交叉推算(triangulate)。
And the last time you move forward with a PARP inhibitor, you had a 1.6 billion up from milestone from a partner. So can you confirm that R&D as a potential revenue is still in the low 20s, I presume it is. But more importantly, could you give us some qualitative guidance on SG&A, which obviously stepped up a lot in Q4 and just where that will land for the full year '24?
而上一次你們推進一個 PARP 抑制劑時,你們從合作夥伴那裡拿到 16 億美元的里程碑預付款(upfront milestone)。所以你能否確認研發(R&D)作為潛在營收仍在 20% 出頭的低位區間(low 20s),我猜是的。但更重要的是,你能否就銷售、一般及行政費用(SG&A)提供一些定性指引?顯然第四季大幅上升,那麼 2024 全年會落在哪個水準?
And then the second question is on your TKM syndrome pipeline. I guess this is all about going after symptomatic diseases like obesity and [detection] heart failure to capture (inaudible) diseases like CKD.
第二個問題是關於你們的 TKM syndrome 產品線。我想這主要是針對像肥胖與 [detection] 心衰竭這類有症狀的疾病,以捕捉(聽不清)像 CKD 這類疾病。
So could you help us understand the opportunity here and the level of investment you're going to put behind this combination of assets, this franchise. And then specifically on the Eccogene drug. We're getting a lot of questions around manufacturing. If you can help us understand how many CMC steps this product has given that with (inaudible) is estimated to be over 30% and therefore, incredibly difficult to scale.
所以你能否幫助我們理解這裡的機會,以及你們打算在這組資產、這個產品群(franchise)背後投入的投資水準?另外,特別是關於 Eccogene 這個藥物。我們收到很多關於製造的問題。你能否幫助我們理解,考量到(聽不清)估計超過 30%,因此極難擴產,這個產品有多少個 CMC(化學、製造與管制)步驟?
Pascal Soriot - CEO & Executive Director
Pascal Soriot - CEO & Executive Director
Aradhana?
Aradhana?
Aradhana Sarin - CFO & Executive Director
Aradhana Sarin - CFO & Executive Director
Sure. So on the SG&A front, if you look at fourth quarter last year, which I think you mentioned is a concern in terms of the step-up. If you look at the last several years, the fourth quarter is always 1 of our largest quarter in terms of SG&A. That does not mean that's the run rate sort of obviously going forward. And then when you look at 2023 and our updated guidance and some of these -- some of the tax transactions and net tax changes that we were -- we had in mind. And we manage the whole P&L. So we chose to invest in certain areas, including some of the launches that you heard about from Ruud and so forth.
好的。關於 SG&A,如果你看去年第四季——我想你提到大家擔心的是費用的跳升——如果你看過去幾年,第四季一向是我們 SG&A 最大的季度之一。這並不代表未來的常態化水準(run rate)就是那樣。然後再看 2023 年、我們更新後的指引,以及其中一些——一些我們原先考量的稅務交易與淨稅務變動。我們是管理整個損益表(P&L)的。因此我們選擇在某些領域加大投資,包括你們從 Ruud 那裡聽到的一些上市推進(launches)等等。
So that sort of explains the fourth quarter of 2023. I think on looking on 2024, we've obviously given guidance on top line and bottom line. I've talked about some of the increase you'll have in finance expenses. I've talked a little bit about the gross margin expectations. And so you can sort of consider that and see where the SG&A growth will be. We are obviously committed to operating leverage, and we do expect that given those puts and takes that the SG&A growth will be lower than the total revenue growth.
這大致解釋了 2023 年第四季的情況。我認為展望 2024 年,我們顯然已就營收端與獲利端提供指引。我也談到你們會看到財務費用的一些增加;也稍微談到毛利率的預期。因此你們可以綜合這些因素,來判斷 SG&A(銷售、一般及行政費用)的成長會落在哪裡。我們顯然致力於提升營運槓桿,而且我們確實預期,在這些利多與利空因素拉鋸之下,SG&A 的成長將低於總營收的成長。
Pascal Soriot - CEO & Executive Director
Pascal Soriot - CEO & Executive Director
Maybe Emmanuel just to add to this. I understand the question also the concern that you mentioned and connecting to James earlier questions. I think it's important to keep in mind that we believe the product sales -- in our guidance, product sales will grow strongly. I mean the guidance is low double digit to low teens, right? So that's a range.
Emmanuel,我補充一下。我理解你提到的問題與擔憂,也把它和 James 先前的提問連結起來。我認為重要的是要記住:我們相信產品銷售——在我們的指引中,產品銷售將會強勁成長。也就是說,指引是低雙位數到低十幾個百分點,對吧?所以那是一個區間。
And product sales will be in that range. So message is, our top line revenue growth is not driven. I mean it's not dependent on this one-off, as you said. Rudd?
而產品銷售會落在那個區間。所以要傳達的訊息是:我們的營收(top line)成長並不是由——我的意思是,它並不依賴你所說的那種一次性因素。Rudd?
Ruud Dobber - Executive Vice-President of BioPharmaceuticals Business Unit
Ruud Dobber - Executive Vice-President of BioPharmaceuticals Business Unit
Yes. So let me first phrase that the opportunity in CKD market. There are more than 800 million patients around the world suffering from CKD. And despite the progress we have seen in the last few years, especially the SGLT2 class, including our on Farxiga, there's still a huge unmet medical need. And hence, our -- let's say, excitement also the products we have in development. Clearly, 1 is the combination of dapagliflozin placebo tenant. And of course, Sharon can talk about that as well, makes us quite bullish about this opportunity.
是的。那我先談 CKD 市場的機會。全球有超過 8 億名患者罹患 CKD(慢性腎臟病)。儘管過去幾年我們看到一些進展,特別是 SGLT2 類別(包括我們的 Farxiga),但仍然存在巨大的未被滿足的醫療需求。因此,我們——可以說——對於這個機會以及我們正在開發中的產品也感到非常振奮。很明顯,其中之一是 dapagliflozin 與 placebo tenant 的組合。當然,Sharon 也可以談談這點,這讓我們對這個機會相當看多。
Now equally, Marc is developing a [Alexion] potential IgAN molecule. This is a space where many companies have left the field. So the kidney space, while we believe that there are huge opportunities based on our pipeline in order to really build a very strong pipeline. So I don't know whether you want to talk a little bit about 1 of the combinations, Sharon.
同樣地,Marc 正在開發一個 [Alexion] 具潛力的 IgAN 分子。這是一個許多公司已經退出的領域。因此,在腎臟領域,我們相信基於我們的研發管線存在巨大機會,能夠真正建立非常強大的產品管線。我不知道你是否想談談其中一個組合,Sharon。
Sharon Barr - Executive Vice-President of BioPharmaceuticals R&D
Sharon Barr - Executive Vice-President of BioPharmaceuticals R&D
Sure, Rudd. So you asked us about the scope of our investment, and then I'll also address your question about our space, our focus on metabolism. So to reframe what Ruud said, there are 20 million people living with CKD and hypertension in the U.S. alone. So clearly, this is a very large market, and it speaks to the interrelatedness of cardio renal and cardiometabolic disease. So thinking about how we can address the different flavors of CKD with our portfolio. We are advancing the baxtro Dato combination. It's in Phase III for CKD. We have Boston Renan combined with dapagliflozin, the miracle Phase II study in CKD with heart failure achieved high-level results at the end of last year.
當然,Rudd。你問到我們投資的範圍,我也會回應你關於我們領域、以及我們對代謝的聚焦。重新表述 Ruud 的說法:僅在美國,就有 2,000 萬人同時罹患 CKD 與高血壓。因此這顯然是一個非常大的市場,也凸顯了心腎疾病與心臟代謝疾病之間的相互關聯性。因此,我們在思考如何用我們的產品組合來處理不同類型的 CKD。我們正在推進 baxtro Dato 的組合;它在 CKD 適應症上已進入第三期。Boston Renan 與 dapagliflozin 的合併,在 CKD 伴隨心衰竭的 miracle 第二期研究中,於去年年底取得了高層級的結果。
And we really look forward to sharing those at an upcoming conference, and we are in the deck of Phase III planning at this point. And then the combination of zibotentan, with dapagliflozin allows us to address CKD with high proteinuria, and we have initiated the ZENITH Phase III trial. So clearly, we're heavily invested in this space, and we view this as an opportunity to manage the complexity of cardiorenal disease and to help people manage their overall health.
我們非常期待在即將到來的會議上分享這些結果,而目前我們也正處於第三期規劃的階段。接著,zibotentan 與 dapagliflozin 的組合,讓我們能夠處理高蛋白尿的 CKD,我們已啟動 ZENITH 第三期試驗。因此很明顯,我們在這個領域投入很深,我們也把它視為一個機會:在管理心腎疾病複雜性的同時,協助人們管理整體健康。
With that in mind, we do think that our metabolism portfolio dovetails very nicely with these efforts to achieve organ protection while managing health because we understand that these diseases are highly interconnected.
基於這點,我們確實認為,我們的代謝產品組合與這些努力能非常良好地相互契合:在管理健康的同時達成器官保護,因為我們理解這些疾病高度相互關聯。
So if we think that there are 64 million people with heart failure worldwide, 15 million alone in Europe -- in Europe alone. And we know that 50% of those patients have renal impairment and 42% have some interrelated metabolic disease. It makes sense that we want to continue to expand our portfolio in the metabolism space. We have been, I think, very open about the acquisition and our interest in the 5004 program. Also this is not our only program. This is 1 piece of our overall focus on metabolic disease.
因此,如果我們認為全球有 6,400 萬名心衰竭患者,僅歐洲就有 1,500 萬名——僅在歐洲。我們也知道其中 50% 的患者有腎功能受損,42% 有某種相互關聯的代謝疾病。那麼我們希望持續擴展代謝領域的產品組合是合理的。我想我們對於收購以及我們對 5004 計畫的興趣一直非常公開。而且這並不是我們唯一的計畫;這只是我們整體代謝疾病聚焦中的一部分。
Moving along at pace. We also have a long-acting amylin as well as a GLP-1 glucagon dual agonist. Speaking briefly to 5004, we are excited about this asset. We are encouraged to see it move forward into 2 Phase IIb trials this year.
我們也在加速推進。我們同時也有一個長效型 amylin,以及一個 GLP-1/胰高血糖素(glucagon)雙重致效劑。簡要談到 5004,我們對這項資產感到興奮。我們也很受鼓舞地看到它今年將推進到兩項第二期 b 試驗。
Pascal Soriot - CEO & Executive Director
Pascal Soriot - CEO & Executive Director
You want to say a few words about the manufacturing steps.
你想談幾句關於製造步驟嗎?
Susan Mary Galbraith - EVP of Oncology Research & Development
Susan Mary Galbraith - EVP of Oncology Research & Development
Actually, I'll say 2 things. The first is that, 1 key focus for 5004 is being able to simplify our manufacturing process and come up with a simpler synthetic route. And together with our collaborators at Eccogene, I think we're making substantial progress on that front. The second thing that I will say continues to speak to the interconnectedness of disease, which is that 5004 as an orally bioavailable molecule is very well suited to potential combinations with other oral molecules in our portfolio. And so I would include in that list, Farxiga as well as our oral PCSK9 inhibitor.
其實我會說兩點。第一,5004 的一個關鍵重點是能夠簡化我們的製造流程,並提出更簡單的合成路徑。與我們在 Eccogene 的合作夥伴一起,我認為我們在這方面取得了實質進展。第二點仍然呼應疾病的相互關聯性:5004 作為一個具口服生體可用性的分子,非常適合與我們產品組合中的其他口服分子進行潛在聯合。因此我會把 Farxiga 以及我們的口服 PCSK9 抑制劑也納入這個清單。
And so we look forward to sharing results of our Phase I trial, which only recently wrapped up. This was a highly controlled 4-week inpatient trial that was piloted by Eccogen. We achieved database lock at the end of December, and we look forward to sharing the data at an upcoming medical conference.
因此,我們期待分享我們第一期試驗的結果,該試驗最近才剛結束。這是一項高度受控的 4 週住院試驗,由 Eccogen 主導。我們在 12 月底完成資料庫鎖定(database lock),並期待在即將到來的醫學會議上分享數據。
Pascal Soriot - CEO & Executive Director
Pascal Soriot - CEO & Executive Director
Maybe 1 quick point is that every focuses on obesity, because there is this big segment of people are not [obesed] their overweight. So they don't need to lose 25% weight. They need to lose a bit of weight and they have metabolic disease sometimes with organ damage as well. And in that segment, which is extremely large and where the payers are more likely to pay managing the various dimensions of the metabolic syndrome with the PCSK9 with Dato, with baxdrostat and being able to combine is going to be a substantial advantage if you have this portfolio that we have in.
也許快速補充一點:大家都聚焦在肥胖,因為有一大群人其實不是[肥胖]而是過重。所以他們不需要減重 25%,他們只需要減掉一些體重,而且他們有代謝疾病,有時也伴隨器官損傷。在那個族群中——規模極其龐大,而且支付方更可能願意付費——用 PCSK9、用 Dato、用 baxdrostat 來管理代謝症候群的各個面向,並且能夠進行組合治療;如果你擁有我們這樣的產品組合,將會是一個重大的優勢。
Simon P. Baker - Head of Pharmaceutical Research
Simon P. Baker - Head of Pharmaceutical Research
Simon Baker from Redburn Atlantic. Two for me, please. Firstly, on Tezspire and Saphnelo. Now they've both been on the market for a while. I wonder if you could give us an update on the characteristics of the prescribers and patients so far for both drugs? Question on Gracell and FasTCAR. If you could just give us an idea of how easily scalable that manufacturing technology is?
我是 Redburn Atlantic 的 Simon Baker。我有兩個問題。第一,關於 Tezspire 和 Saphnelo。它們都已上市一段時間了,想請你們更新一下:到目前為止,這兩個藥物的處方醫師與患者族群特徵是什麼?第二個問題關於 Gracell 和 FasTCAR:你們能否說明一下,這項製造技術的可擴展性(scalability)有多容易?
And also, a bit more color on the comment that Gracell have made in the past that there was a substantial manufacturing cost advantage here, which sounds like it could be quite significant as you move into autoimmune areas. Any color on that would be very much appreciated.
另外,也希望你們能更具體說明一下 Gracell 過去提到的評論:這裡存在顯著的製造成本優勢;聽起來當你們進入自體免疫領域時,這可能會非常重要。若能提供一些補充說明,我將非常感謝。
Ruud Dobber - Executive Vice-President of BioPharmaceuticals Business Unit
Ruud Dobber - Executive Vice-President of BioPharmaceuticals Business Unit
Yes. Let me first start with your question about Tezspire. The product is doing very well, not only in the United States but also equally in the markets we have just launched. We have leading NBRx, or new-to-brand market shares in countries like Spain and Germany. The patient population is a very interesting one. It's primarily the patients who have, let's say, a moderate or normal is in the full count but are allergic. So the low T2 patient population is highly dominant in what we see so far. But equally, we also know from our clinical studies that Tezspire0 is also very well established in the highest in the fills in the United States. So the broad utility of the products and no need for a biomarker, no need for phenotyping, makes it a highly attractive choice for especially allergies and more and more pulmonologists as well.
好的。我先從你關於 Tezspire 的問題開始。這個產品表現非常好,不僅在美國,也同樣在我們剛上市的市場表現出色。我們在西班牙、德國等國家取得領先的 NBRx(新處方)或新進品牌市占。患者族群非常有意思:主要是那些——可以說——嗜酸性球(eosinophil)計數中等或正常、但有過敏的患者。因此,到目前為止我們看到的以低 T2 患者族群為主。但同樣地,我們也從臨床研究知道,Tezspire0 在美國嗜酸性球最高的族群中也已非常確立其療效。因此,產品的廣泛適用性、且不需要生物標記、不需要分型(phenotyping),使其成為非常有吸引力的選擇,特別是對過敏患者而言,而且也越來越受到肺科醫師的青睞。
So we have high expectations and together with our partner MG and I think it's fair to say that the product is on its way to become a blockbuster anytime soon. So that's one. Saphnelo is another very nice story. It's the only interferon receptor antagonist. It has blown our lupus is a disease with multiple manifestations and multiple organ manifestations. It's particularly very impactful on skin disease, and we have seen very, very strong feedback from rheumatologists that patients primarily with skin manifestations are reacting very well on Saphnelo. Equally, only operating in the [inter veneous] markets as we speak.
因此我們抱持很高的期待,並且與我們的合作夥伴 MG 一起,我想可以公平地說,這個產品正朝著在不久的將來成為重磅藥(blockbuster)的方向前進。這是第一點。Saphnelo 則是另一個非常好的故事。它是唯一的干擾素受體拮抗劑。它已改變了我們對狼瘡的——狼瘡是一種具有多種表現型、且會影響多個器官的疾病。它對皮膚病變特別有顯著影響,我們也從風濕科醫師那裡收到非常、非常強烈的回饋:主要以皮膚表現為主的患者對 Saphnelo 的反應非常好。同樣地,目前如我們所見,它只在[靜脈注射]市場中運作。
So we are doing for the last 1.5, 2 years, relatively large study for subcutaneous formulation. And I truly believe, hopefully next year, that study will read out, and we have a positive readout as we'll provide another clear opportunity. And as Sharon mentioned in her remarks, we are very keen to move Saphnelo also in multiple other indications in order to further grow the brand to also equally a blockbuster brands in the next few years.
因此,在過去 1.5 到 2 年,我們一直在針對皮下劑型進行相對大型的研究。我也真心相信——希望明年——該研究將會讀出結果,而且我們會有正面的讀出,這將為我們帶來另一個明確的機會。正如 Sharon 在她的發言中提到的,我們也非常積極地希望將 Saphnelo 推進到多個其他適應症,以進一步擴大品牌規模,並在未來幾年同樣成長為一個重磅品牌。
Pascal Soriot - CEO & Executive Director
Pascal Soriot - CEO & Executive Director
Thanks, So Susan, do you want to comment on (inaudible)?
謝謝。所以 Susan,你想就(聽不清)發表評論嗎?
Susan Mary Galbraith - EVP of Oncology Research & Development
Susan Mary Galbraith - EVP of Oncology Research & Development
So as I mentioned in my prepared remarks. The actual time that you need to manufacture the [Fasco] is substantially shorter than for some other currently commercially available CAR-T therapies. That's 1 component of the turnaround time, obviously. So it's 1 component also of the manufacturing cost. I think it does help with scalability because the amount of time that you need to process each individual patient's batch is also shorter within the manufacturing facility. So what that means is that you do get increased capacity for a given size of the manufacturing building that you've created.
正如我在事先準備的發言中提到的,[Fasco] 的實際製造時間,明顯比目前市面上一些已商業化的 CAR-T 療法要短。這顯然是周轉時間的一個組成部分,因此也構成製造成本的一個部分。我認為這確實有助於可擴展性,因為在製造設施內,你需要處理每位病患個別批次的時間也更短。這代表在你所建置的既定製造廠房規模下,可以獲得更高的產能。
So that's important. But also, it means that you can be more predictable about the delivery. And because you are actually generating a smaller total number of the cells that have to be delivered to the patient the likelihood of success of each of those is higher. So all of these things, I think, contribute to the overall benefit that we see from the Fasco process.
這點很重要。同時,這也意味著你可以更可預測地進行交付。而且因為你實際上產生、需要交付給病患的細胞總數較少,因此每一次交付成功的機率也更高。我認為所有這些因素,都共同促成了我們從 Fasco 製程中看到的整體效益。
Pascal Soriot - CEO & Executive Director
Pascal Soriot - CEO & Executive Director
Thanks, Susan. Maybe we could take 1 online question. Tim Anderson of Wolfe Research. Tim, over to you.
謝謝你,Susan。也許我們可以接一個線上提問。Wolfe Research 的 Tim Anderson。Tim,交給你。
Timothy Minton Anderson - MD of Equity Research
Timothy Minton Anderson - MD of Equity Research
Any headwinds to revenue growth for individual key brands in 2024 that you'd like to call out relative to where you see consensus. So in rare diseases, you're facing some new competition? In oncology, you talked about in HER2, but what about Tagrisso or Calquence. Calquence in the U.S. seems to be stalling out, for example? .
相較於你們對市場共識的看法,2024 年各個關鍵品牌的營收成長是否有任何逆風因素是你們想特別點出的?例如在罕見疾病領域,你們面臨一些新的競爭?在腫瘤領域,你們談到 HER2,但 Tagrisso 或 Calquence 呢?例如 Calquence 在美國似乎正在停滯?
And then second question on Dato. Any risk to approval in the U.S. in lung and nonsquamous based on what you have today? To me, the regulatory precedents as it should be low risk, and you should get approved, but that's not necessarily the consensus view. So what's your confidence here? And what happens if OS misses and non-screamers remain supportive, but doesn't formally hit?
第二個問題關於 Dato。以你們目前掌握的資料,在美國針對肺癌與非鱗狀(適應症)的核准是否有任何風險?在我看來,依照既有的監管先例,風險應該不高,應該會獲准,但這不一定是市場共識。你們在這裡的信心如何?如果 OS 未達標,而非鱗狀仍然支持,但沒有正式達到(統計)門檻,會怎麼樣?
Pascal Soriot - CEO & Executive Director
Pascal Soriot - CEO & Executive Director
Tim, I'm going to propose Marc, you cover (inaudible) and the general competitive environment. Dave, you could cover Calquence and Tagrisso. And Tagrisso maybe also talk about not only the headwinds but also the potential upsides. And then Susan, you cover Dato.
Tim,我建議由 Marc 來回答(聽不清)以及整體競爭環境。Dave 你可以談 Calquence 和 Tagrisso。至於 Tagrisso,也請不只談逆風,也談談可能的上行空間。然後 Susan 你來談 Dato。
Susan Mary Galbraith - EVP of Oncology Research & Development
Susan Mary Galbraith - EVP of Oncology Research & Development
Yes.
好的。
Marc Dunoyer - CEO of Alexion & Chief Strategy Officer
Marc Dunoyer - CEO of Alexion & Chief Strategy Officer
So let me start with (inaudible). So basically, the headwind that we can anticipate is the introduction of biosimilars in the PNH indication. Two competitors have started to gain approval in 2023. The impact on '23 is still very limited, but obviously, this could increase over time. The way we counteract this headwind is by converting as fast as possible from Soliris to Ultomiris and in the main indications both neurology indication as well as PNH the conversion is very high. It's in the magnitude of 80%. That's the first thing.
我先從(聽不清)開始。基本上,我們可以預期的逆風是:在 PNH 適應症中引入生物相似藥。兩個競爭對手在 2023 年已開始取得核准。對 2023 年的影響仍非常有限,但顯然隨時間可能會增加。我們因應這個逆風的方式,是盡可能快速地將病患從 Soliris 轉換到 Ultomiris;在主要適應症——神經科適應症以及 PNH——轉換率非常高,大約在 80% 的量級。這是第一點。
The -- where we're also sustaining the growth of the complement franchise is buying -- expanding our regional presence. And we have augmented significantly in 2023. We still have more work to do in '24. We are increasing the number of approval and reimbursement for Soliris as well as for Ultomiris.
另外,我們維持補體產品線成長的方式,是擴大我們的區域布局。我們在 2023 年已大幅強化,2024 年仍有更多工作要做。我們正在增加 Soliris 與 Ultomiris 的核准與給付(報銷)數量。
And lastly, this is a long-term work that we have been doing to make this franchise sustainable, we are continuing to develop new indications. We have anymore that has been approved recently in Europe and Japan with very rapid uptake. We are soon to get the U.S. approval, but we will also continue with other indications, which are presently in Phase III. So not only on the C5. And then we have also -- I forgot to buttify. We have the nobody bispecific 1720 givilimab that is well advanced in Phase III and should be coming to the market in (inaudible) very soon. So there is a future -- a very bright future for the C5 franchise and the complement franchise overall.
最後,作為我們長期以來為了讓這個產品線可持續而進行的工作之一,我們持續開發新的適應症。我們有一個(聽不清)最近已在歐洲與日本獲准,且採用速度非常快。我們很快也將取得美國核准;同時我們也會持續推進其他目前處於第三期的適應症。因此不僅僅是在 C5 上。然後我們也有——我忘了補充——我們的(聽不清)雙特異性 1720 givilimab,第三期進展良好,應該很快就會在(聽不清)上市。因此,C5 產品線以及整體補體產品線的未來——非常光明。
David Fredrickson - Executive Vice-President of Oncology Business Unit
David Fredrickson - Executive Vice-President of Oncology Business Unit
Turning to oncology and Tim, on your question. So very directly on your first question, which is, are there any places where there's headwinds relative to consensus? I commented in my prepared remarks on the only 1 that I would call out, but I think it's important, which is that in Japan, in February, we had repricing on Imfinzi that I'm not sure is built into all of the models moving ahead, and we do anticipate because of some changes from weight-based to fixed dosing that we will see another in Japan, Imfinzi price adjustment.
回到腫瘤領域,Tim,針對你的問題。就你第一個問題——也就是相較於市場共識,是否有任何地方存在逆風——我在事先準備的發言中提到,我唯一會特別點出的就是日本的情況,而且我認為這很重要:在日本,我們在 2 月對 Imfinzi 進行了重新定價,我不確定所有往後的模型都已納入這點;而且我們預期,由於從按體重計價改為固定劑量等變更,我們將在日本看到 Imfinzi 的另一輪價格調整。
With that said, on the specific question about Tagrisso. I'm enthusiastic about where Tagrisso ends the year and where it comes into next year. As I mentioned, we're seeing good underlying demand growth sequentially within the U.S. and within Europe. And I think that is coming on the heels of ADAURA and FLAURA performing well. We've got an opportunity in China despite the competition that we're seeing there to move out of this anticorruption shadow that I think has affected the ability to be able to really take advantage of a leadership position that we have, all doing the right thing, but just in terms of access in general to oncologists has been more limited.
話雖如此,針對 Tagrisso 的具體問題,我對 Tagrisso 今年年底的表現以及進入明年的狀態感到非常振奮。正如我提到的,我們在美國與歐洲都看到良好的基礎需求,且呈現逐期成長。我認為這是在 ADAURA 與 FLAURA 表現良好的帶動下發生的。儘管在中國我們看到競爭,但我們仍有機會走出我認為影響我們的反腐陰影——我們都在做正確的事——但就一般而言,對腫瘤科醫師的接觸管道確實更受限。
We've got FLAURA2, which, knock on wood, we'll see an approval on here sometime within the year, we've got LAURA, which I think is a really important catalyst that will read out again here within the first half. So I look at the outset on this. And I think also on a competitive landscape basis, FLAURA2 positions us pretty nicely. On Calquence, no question that we've got a competitive environment, and we've got a direct competition. But I also like what our U.S. and European teams have been able to do in the face stack competition.
我們有 FLAURA2,若一切順利,我們應該會在今年某個時間點看到核准;我們也有 LAURA,我認為這是一個非常重要的催化劑,預計也會在上半年再次讀出。我從一開始就這樣看待。此外,就競爭格局而言,FLAURA2 也讓我們的定位相當不錯。至於 Calquence,毫無疑問我們面臨競爭環境,而且是直接競爭;但我也很欣賞我們美國與歐洲團隊在激烈競爭下所做到的成果。
I think that within that, we've got a leadership position within frontline CLL that we've been able to maintain. I think if you take some of the months or the quarterly phasing out of the situation, we've seen really good, strong underlying demand growth on Calquence throughout the entirety of the year.
在這之中,我們在一線 CLL 的領導地位一直得以維持。我認為如果把某些月份或季度的節奏因素剔除,我們在 Calquence 上全年都看到非常良好且強勁的基礎需求成長。
I'm hopeful and optimistic that as co-pay within the U.S. is lowered. Pascal talked about this in his remarks, and we see affordability go from patients having to pay 5% of the catastrophic to 0, and therefore, a co-pay cap that is $2,000 that this is going to give patients the ability to be able to stay on and have greater adherence to continuous treatment to progression on BTK therapy.
我抱持希望且樂觀,隨著美國的自付額(co-pay)降低——Pascal 在他的發言中談到這點——當可負擔性從病患必須支付「災難性支出」的 5% 降到 0%,因此自付額上限為 2,000 美元時,這將使病患更有能力持續用藥,並在 BTK 治療上維持連續治療至疾病進展,從而提高依從性。
So again, we have to see that play out. We have to see how that works through. But I think that these are elements that give me enthusiasm about the oncology portfolio and the opportunities in front of us.
所以我們仍需觀察其實際發展,並看它如何逐步落地。但我認為這些因素讓我對腫瘤產品組合以及我們面前的機會感到振奮。
Pascal Soriot - CEO & Executive Director
Pascal Soriot - CEO & Executive Director
I think this co-pay cap, it should really not be underestimated because if you look at the U.S. system on the Medicare side, it is going to be a very, very good system. I mean, many countries have co-pays. I mean Australia has co-pay, Switzerland had co-pay, many countries have co-pays. And here in the United States, people, patients are going to be able to say, "I'm not going to pay more than $2,000 a year, regardless of how many drugs are received, regardless of how much they cost $2,000".
我認為這個自付額上限真的不應被低估,因為如果你看美國的制度,在 Medicare 端,這將會是一個非常、非常好的制度。很多國家都有自付額,例如澳洲有自付額、瑞士也有自付額,許多國家都有自付額。而在美國,民眾、病患將能夠說:「不管用了多少藥、不管藥有多貴,我一年最多只付 2,000 美元,就是 2,000 美元。」
Now you might say $2,000 is a fair amount of money. But if you have a car insurance or house insurance, that's going to cost you at least that and many people can afford this.
你可能會說 2,000 美元是一筆不小的錢。但如果你有汽車保險或房屋保險,至少也會花到這個金額,而且很多人是負擔得起的。
And it's a great level of reassurance in terms of taking your medicines and being adherent to them. And for us, it will mean a reduction of free goods, we have to give, which has been increasing substantially in the last few years as people -- more and more people cannot afford to cover the co-pays.
而且這在按時服藥並遵從用藥方面,能帶來很高程度的安心感。對我們而言,這也意味著我們必須提供的免費藥品會減少;過去幾年這一項大幅增加,因為人們——越來越多人無力負擔自付額(co-pay)。
Luisa Caroline Hector - Co-Head of Global Pharmaceutical Team
Luisa Caroline Hector - Co-Head of Global Pharmaceutical Team
It's Luisa Hector from Berenberg.
我是來自貝倫貝格(Berenberg)的 Luisa Hector。
Susan Mary Galbraith - EVP of Oncology Research & Development
Susan Mary Galbraith - EVP of Oncology Research & Development
Next question on Dato.
下一個關於 Dato 的問題。
Pascal Soriot - CEO & Executive Director
Pascal Soriot - CEO & Executive Director
No, no, no. Sorry.
不,不,不。抱歉。
Susan Mary Galbraith - EVP of Oncology Research & Development
Susan Mary Galbraith - EVP of Oncology Research & Development
So, can I answer? Okay. So first of all, thanks for the questions. We're confident that Dato-DXd is going to be important medicine in the treatment of non-small cell lung cancer. Obviously, we've been having ongoing discussions with the regulatory authorities. TL01 is a trial with a dual primary end point.
那我可以回答嗎?好的。首先,謝謝提問。我們有信心 Dato-DXd 將會是治療非小細胞肺癌的重要藥物。顯然,我們一直在與監管機關持續討論。TL01 是一項具有雙主要終點的試驗。
Obviously, we met PFS as one of those primaries, but OS is going to be important in the second to third line setting. When you think historically other than checkpoint inhibitors no medicines have demonstrated OS benefit and doses tax will currently remains the standard of care.
顯然,我們已達成 PFS 作為其中一個主要終點,但在二線到三線治療情境下,OS 會很重要。回顧歷史,除了免疫檢查點抑制劑之外,沒有藥物證明具有 OS 受益,而多西他賽目前仍是標準治療。
I'll remind you that in the non-squamous population, the data that we presented at ASCO, we showed that the hazard ratio in the non-squamous for OS was 0.77 with a confidence interval that only just overlapped once. So it was 1.01 at the upper end.
我提醒各位,在非鱗狀細胞族群中,我們在 ASCO 發表的數據顯示,非鱗狀細胞的 OS 危險比為 0.77,且其信賴區間僅在上緣略微重疊一次,也就是上限為 1.01。
So I think that shows that we're not just seeing a progression-free survival benefit, but there's a strong trend to OS within that patient population. So quite often as is normal as the OS events mature, we'll often have an update of the OS during a period of review, and we'd anticipate that during the period of review for TL01, we can update the OS.
所以我認為這顯示我們不只是看到無惡化存活期(PFS)的受益,在該病人族群中也呈現出對總存活期(OS)的強烈趨勢。因此,通常如同常態,隨著 OS 事件逐漸成熟,我們往往會在審查期間更新 OS;我們預期在 TL01 的審查期間可以更新 OS。
Luisa Caroline Hector - Co-Head of Global Pharmaceutical Team
Luisa Caroline Hector - Co-Head of Global Pharmaceutical Team
Luisa at Berenberg. I would like to ask is it correct to comment on the Icosavax deal and just the attractions of the assets there and the opportunity to enter the RSV market?
貝倫貝格的 Luisa。我想請問,是否可以評論一下 Icosavax 的交易,以及那裡資產的吸引力與進入 RSV 市場的機會?
And then also maybe to pivot from that slightly bigger picture question. But essentially a margin question, sorry. You've shown us the fabulous pipeline progress, the breadth and depth. We see the entry into new therapeutic areas, the modalities, vaccines, DC T cell therapies, et cetera. So it's really bubbling. So really, it's about how you can be so confident in some margin expansion midterm. How can that happen? Is there a point where selling costs, the infrastructure stabilizes? How do these fabulous products compete for R&D budget? Is it about strict almost attrition, making sure absolutely the best projects are moving forward? So just any color on that so that you can give us confidence in the ability to raise margins given all the excitement within the pipeline?
另外也許從那個稍微更宏觀的問題轉到——但本質上是個毛利率問題,抱歉。你們向我們展示了令人驚豔的研發管線進展、廣度與深度。我們看到你們進入新的治療領域、不同的技術平台、疫苗、DC T 細胞療法等等,真的非常蓬勃。所以問題在於:在中期你們如何能對毛利率擴張如此有信心?這如何發生?是否有一個時間點,銷售成本與基礎設施會趨於穩定?這些精彩產品如何競爭研發預算?是否關鍵在於嚴格、近乎汰弱留強,確保只有最好的專案能往前推進?希望你們能提供一些補充,讓我們對在管線如此令人振奮的情況下仍能提升毛利率的能力更有信心。
Iskra Reic - Executive Vice-President of Vaccines & Immune Therapies
Iskra Reic - Executive Vice-President of Vaccines & Immune Therapies
Thanks Lisa, for the question, for your interest. So the proposed acquisition of Icosavax really strenghthened our lead stage pipeline in vaccine and immune therapies. Because the Icosavax lead asset is the combination RSV and PV vaccine. That is Phase III ready.
謝謝你,Lisa,謝謝你的提問與關注。擬議收購 Icosavax 確實強化了我們在疫苗與免疫療法的後期研發管線。因為 Icosavax 的主力資產是 RSV 與 PV 的聯合疫苗,已具備進入第三期的條件。
And that is important to us for 2 different perspective and one side, this is a next-generation vaccine technology within the respiratory vaccines because it's a protein virus like particle vaccine and importance of that vaccine is that they have a potential to be better, more effective and more safe than a non-VLP vaccine.
這對我們而言從兩個不同角度都很重要。一方面,這是呼吸道疫苗領域的下一代疫苗技術,因為它是蛋白質病毒樣顆粒(VLP)疫苗;其重要性在於,相較於非 VLP 疫苗,它可能更好、更有效且更安全。
So basically, what you can expect to see from those vaccine is to have a higher efficacy and a longer durability of the fact and, at the same time, better safety profile. The second important aspect of this is that this is a combination of RSV and HMPV vaccine. And although there are a number -- you can argue that there are a number of RSV vaccines for the other population available in the market. There are no -- neither preventative or therapeutic options for HMPV. And maybe that's the virus that many of you even never heard about, but I can tell you that the RSV and HMPV are basically among leading causes of the severe respiratory infections. And if you look at the numbers of the hospitalization and infections are basically in the similar rate between HMPV, RSV and flu. And therefore, we feel excited to use this vaccines on 1 side, accelerate and bring it to patients as soon as possible.
基本上,你可以期待這類疫苗具有更高的有效性與更長的保護持久性,同時也有更好的安全性特徵。第二個重要面向是,這是一個 RSV 與 HMPV 的聯合疫苗。雖然你可以說市場上已經有多款針對其他族群的 RSV 疫苗,但對 HMPV 並沒有——無論預防或治療——的選項。也許很多人甚至沒聽過這個病毒,但我可以告訴你,RSV 與 HMPV 基本上都是造成嚴重呼吸道感染的主要原因之一。若看住院與感染的數據,HMPV、RSV 與流感的比率其實相近。因此,我們對這款疫苗感到興奮:一方面要加速推進,盡快帶給病人。
On the other side, it's a great strategic fit because it really builds on AztraZeneca experience in RSV as well as builds on our therapeutic leverage and serving the patients that are at risk of respiratory diseases. And just at the end, I need to mention that deal is still subject to closing.
另一方面,這在策略上也非常契合,因為它建立在阿斯特捷利康(AstraZeneca)在 RSV 的經驗之上,也強化我們在治療端的優勢,服務有呼吸道疾病風險的病人。最後我需要提到,這筆交易仍需完成交割。
Pascal Soriot - CEO & Executive Director
Pascal Soriot - CEO & Executive Director
So Lisa, your second question, the R&D spend, as we've said before, we expect to keep in the low 20s percentage as a percentage of revenue. And our improvement will come from SG&A. And so we are very committed to achieving this margin expansion in the midterm, as we've communicated for now quite some time. We are on track and we're committed to this and really is about leveraging the critical mass and some of these products that have required sorry, a lot of promotion at scale in terms of promotional efforts.
所以 Lisa,你的第二個問題關於研發支出:如同我們之前所說,我們預期研發支出占營收比重會維持在 20% 出頭。而我們的改善將來自 SG&A。因此,我們非常致力於在中期達成這個毛利率擴張目標,這也是我們溝通已久的方向。我們進度符合預期,也會持續投入;關鍵在於運用規模效益,以及部分產品在推廣上——抱歉——需要大量、規模化的推廣投入。
If you look at the Breztri, look at -- I mean, Farxiga will be even potentially declining in promotion. So we can manage with this large SG&A spend. We have to manage, I should say, so that we can actually deliver this midterm ambition.
如果你看 Breztri,再看——我的意思是,Farxiga 的推廣甚至可能會下降。因此,我們可以在這樣龐大的 SG&A 支出下進行管理;我應該說,我們必須管理好,才能真正實現這個中期目標。
Now the long-term ambition in operating margin is something we will define over the next couple of years as we see the progression of the pipeline. Because quite honestly, what we've seen in the last 2 to 3 years is an expansion of our pipeline.
至於長期的營業利益率目標,我們會在未來幾年隨著管線進展來界定。因為坦白說,過去 2 到 3 年我們看到的是研發管線的擴張。
We have a number of products now in the pipeline, the PCSK9, the (inaudible) of course, baxdrostat that we believe can drive a lot more top line growth than could have been anticipated, say, a couple of years ago. So depending on how the pipeline shapes up. We'll have to decide what our percentage margin ambition is, but I've said many times before, and I want to be clear, what we focus on is the absolute dollar value and the cash flow we deliver.
我們現在管線中有多個產品,例如 PCSK9、(聽不清)以及當然還有 baxdrostat;我們相信這些能帶動比兩年前所能預期的更高營收成長。因此,取決於管線的樣貌,我們必須決定我們的毛利率目標百分比。但我之前多次說過,也想講清楚:我們關注的是絕對金額與我們所交付的現金流。
So if we had -- and I'm not saying we would, but if we had to compromise on the further future progression of operating margin beyond the mid-30s, we had to comprise on the percentage, it will be because we deliver more top line. And the same or more absolute dollar value in operating profit and cash flow. Becasue ultimately as I keep saying we deliver value to shareholders with dollars not percentage, right? And so really, if we can deliver even more growth than we had anticipated 2 years ago, it will drive more profit.
所以如果我們——我不是說我們會,但如果我們必須在中期 30% 中段之後的更長期營業利益率進一步提升上做出取捨、在百分比上做出妥協,那會是因為我們帶來了更高的營收成長,以及相同或更高的營業利益與現金流的絕對金額。因為最終,如我一直所說,我們是用「金額」而不是「百分比」為股東創造價值,對吧?因此,如果我們能交付比兩年前預期更高的成長,就會帶來更多利潤。
And so we'll have to adjust this over the next couple of years based on our pipeline. But with the firm commitment that in absolute value, we will deliver a substantial growth in top line but also in bottom line growth.
因此,我們會在未來幾年依據管線情況做調整。但我們堅定承諾:以絕對金額來看,我們將交付顯著的營收成長,同時也交付顯著的獲利成長。
Eric Le Berrigaud - Research Analyst
Eric Le Berrigaud - Research Analyst
Eric Le Berrigaud, Stifel. Two questions. First for Aradhana. Coming back on 1 of your comment before on CapEx. So CapEx anticipated to grow by maybe as much as 50%. How should we think about this going forward? Is it a 1-year sharp increase? Or should we think about CapEx staying around $2 billion for the next few years or thinking percentage of revenues? Or how should we model this?
我是 Stifel 的 Eric Le Berrigaud。我有兩個問題。第一個給 Aradhana,回到你先前關於資本支出(CapEx)的評論。CapEx 預期可能成長多達 50%。我們應該如何看待未來?這是一年期的急遽增加嗎?還是未來幾年 CapEx 會維持在約 20 億美元?或是應以營收百分比來思考?我們應該如何建模?
And maybe the second question for you, Ruud and Sharon, about maybe the next wave of innovation into the biologics in respiratory. We see 1 competition coming with long-acting [IO size] We see more interest for the TSLP targeting in -- also with long acting, but also combining with other targets. How -- what is AstraZeneca doing for the next wave and to build on the existing franchise?
第二個問題可能給你、Ruud 和 Sharon,關於呼吸領域生物製劑的下一波創新。我們看到有競爭者推出長效型的 [IO size];也看到對 TSLP 標靶的興趣增加——同樣有長效型,也有與其他標靶的組合。阿斯特捷利康正在做什麼來布局下一波、並在既有產品線上持續擴大優勢?
Pascal Soriot - CEO & Executive Director
Pascal Soriot - CEO & Executive Director
Aradhana?
Aradhana?
Aradhana Sarin - CFO & Executive Director
Aradhana Sarin - CFO & Executive Director
Sure. Thank you for the question. On CapEx, if you look over the last several years and you benchmark us against our peers, we've actually underinvested in CapEx substantially. And that's also because we had other opportunities to invest and so forth. But when you look forward, and especially this year, we've given guidance on specifically, we're investing behind a number of products that we're bringing forward, right? So we just announced the cell therapy facility in Rockwell. So again, Susan talked about the whole cell therapy ambition. That requires upfront investment in CapEx. And again, some of that is at risk, obviously. We're investing in our own API plant in Dublin. And that's also because we're trying to become more self-sufficient as it relates to API.
好的,謝謝你的問題。關於 CapEx,如果你回顧過去幾年並與同業比較,我們其實在 CapEx 上明顯投資不足。這也因為我們有其他投資機會等等。但展望未來,特別是今年,我們已給出明確指引:我們正在為多項即將推進的產品加大投資,對吧?我們剛宣布在 Rockwell 的細胞治療設施。因此,Susan 談到整體細胞治療的企圖心,這需要前期的 CapEx 投入。而且其中一部分顯然是有風險的。我們也在都柏林投資自有的 API 工廠,這也是因為我們希望在 API 方面更自給自足。
We announced a inhaled facility in Qingdao, and that's to fulfill the demand that we expect for breast free for example, to come out of China. And in addition, we are investing in our ERP systems, which as I would say, for many, many years being under invested in. So there are a number of these investments that we're making behind our pipeline. And you've seen from recent transactions and other investments that some of our peers are doing and have done that it has become increasingly important to have more and more self-reliant supply chains. And oftentimes, you see companies not being able to fulfill their growth ambition because of underinvestment in supply. So we're sort of getting ahead of this curve for the pipeline and the new opportunities.
我們宣布在青島設立一座吸入製劑工廠,這是為了滿足我們預期的需求,例如 Breztri 這類產品預計將從中國走出來的需求。此外,我們也在投資我們的 ERP 系統;我會說,這些系統多年來一直投資不足。因此,我們正在管線背後進行多項投資。你也從近期交易以及我們一些同業正在做、也已經做過的其他投資中看到,建立愈來愈自給自足的供應鏈變得愈來愈重要。很多時候,你會看到企業因為供應端投資不足而無法實現其成長企圖。因此,我們算是在為管線與新機會提前布局、走在曲線之前。
Pascal Soriot - CEO & Executive Director
Pascal Soriot - CEO & Executive Director
One of the things that this plant in Qingdao, will support this our growth ambition in the respiratory market in China. If you look at COPD in China is totally underdeveloped. I mean the treatment is -- the disease is extremely prevalent, pollution, smoking, aging. So there's a lot of COPD, but the market is totally underdeveloped. Today, we have 65 or more percent market share with Breztri in the triple segment in China. And as the market develops, we're working very hard and expanding it as we market develop and we have local manufacturing, there's enormous potential for products like Breztri and that is really why we decided to make this investment.
青島這座工廠將支持我們在中國呼吸市場的成長企圖。若你看中國的 COPD,整體仍然非常未開發。我的意思是,治療——這個疾病極為普遍,污染、吸菸、老化等因素使然。所以 COPD 很多,但市場完全未開發。今天,我們在中國三聯療法細分市場中,Breztri 的市占率達到 65% 或更高。隨著市場發展,我們正非常努力地擴大市場;當市場發展且我們具備在地製造時,像 Breztri 這樣的產品有巨大的潛力,這也正是我們決定進行這項投資的原因。
Ruud Dobber - Executive Vice-President of BioPharmaceuticals Business Unit
Ruud Dobber - Executive Vice-President of BioPharmaceuticals Business Unit
Quickly regarding, let's say, the future of the biologics, and Sharon will comment on the science in a moment. So despite the progress we have seen in the last few years was like Tezspire and Fasenra. It's also a fact of life that there's still a high unmet medical need and that remains. So still patients are suffering from multiple exacerbations in the severe asthma segment as well as COPD.
快速談一下,例如,生物製劑的未來,Sharon 等一下會就科學面做評論。儘管過去幾年我們看到像 Tezspire 和 Fasenra 的進展,但現實是仍然存在高度未被滿足的醫療需求,而且這點依然如此。因此,在重度氣喘族群以及 COPD 中,仍有患者正遭受多次急性惡化之苦。
So we're going to bet on new mode of actions, [TNT] IL-33 is clearly 1 of the examples I'm sure Sharon will say a little bit more about that. But also, we have an anti-tSip in development. And it will be quite spectacular to have an inhaled biologic in order to help those patients suffering from a very severe disease. So new mode of actions, hopefully will unlock the power of those medicines and this indication. And you will see, I think, a lot of studies in the next few years, both in asthma and COPD in order to -- yes, to generate the evidence that it can work.
因此我們將押注於新的作用機轉,[TNT] IL-33 顯然是其中一個例子,我相信 Sharon 會再多說一些。此外,我們也有一個抗 tSip 正在開發中。若能有一個吸入式生物製劑來幫助那些罹患非常嚴重疾病的患者,將會相當驚人。新的作用機轉,希望能釋放這些藥物在此適應症上的力量。我想你會看到,未來幾年在氣喘與 COPD 方面會有很多研究,以便——是的——產生其可行的證據。
Sharon Barr - Executive Vice-President of BioPharmaceuticals R&D
Sharon Barr - Executive Vice-President of BioPharmaceuticals R&D
So I'll build on that and really continue forward with Ruud's message, in which we are proud of both following the science and thinking about patient needs as we create our next wave of therapeutics. So we're aware that patients with respiratory disease with asthma and COPD, are first treated in the community and then progressed to specialty care. And so we're creating a range of therapeutics that are able to meet the needs of their care providers, but also building on the science that we increasingly understand about these diseases.
我會在此基礎上延伸,並延續 Ruud 的訊息:我們以遵循科學、並在打造下一波治療方案時思考患者需求為榮。我們知道,患有呼吸道疾病(氣喘與 COPD)的患者,通常先在社區接受治療,之後才進展到專科照護。因此,我們正在打造一系列治療方案,既能滿足其照護提供者的需求,也建立在我們對這些疾病日益加深的科學理解之上。
So in asthma, building on our success with Fasenra and Tezspire, we're moving forward to thinking about how tozorakimab can be effective there. Tozorakimab is a differentiated therapeutic in that this anti-IL-33 is hitting both the ST2 and the [RAGE ETFI] pathways. So it's able to address the inflammatory piece of the disease as well as mucus production and tissue remodeling, which we think is going to be very powerful for patients.
在氣喘方面,基於我們在 Fasenra 與 Tezspire 的成功,我們正推進並思考 tozorakimab 在此的有效性。Tozorakimab 是一個具差異化的治療,因為這個抗 IL-33 同時作用於 ST2 與 [RAGE ETFI] 路徑。因此,它既能處理疾病的發炎面向,也能處理黏液生成與組織重塑,我們認為這對患者將非常有力。
And thinking about how patients are accessing their care, moving into the prebiologic space with an inhaled T-slip which we think is a very novel mode of delivery and will allow us to broaden this modality to a larger number of patients as well as an inhaled JAK inhibitor and an oral FLAP inhibitor. So really expanding our science in the pre-biologic space.
並且考量患者如何取得照護,我們正進入生物製劑前(prebiologic)領域,開發一種吸入式 T-slip;我們認為這是一種非常新穎的給藥方式,將使我們能把這種治療模式擴及更多患者;同時也有一個吸入式 JAK 抑制劑與一個口服 FLAP 抑制劑。也就是說,我們正在生物製劑前領域大幅擴展我們的科學布局。
Thinking about COPD, which is still a major unmet medical need worldwide, building on our success with Breztri and again, thinking about how we're delivering an inhaled T-slip in the prebiologic space, offering patients those options as well as an IRAK4 inhibitor, and again, evaluating midiparstat in that space. So we are offering patients a number of different opportunities to address their disease with their general practitioners and then also to access biologics and different mechanisms as they're moving into specialty care. I hope that answers your question.
談到 COPD——這在全球仍是重大的未被滿足醫療需求——我們在 Breztri 的成功基礎上,再次思考如何在生物製劑前領域提供吸入式 T-slip,讓患者有這些選項;同時也有 IRAK4 抑制劑,並再次在該領域評估 midiparstat。因此,我們為患者提供多種不同機會:先在全科醫師端處理其疾病,之後在進入專科照護時,也能取得生物製劑與不同機轉。我希望這回答了你的問題。
Unidentified Analyst
Unidentified Analyst
So again to add on the IL-33, it looks like even physicians have seen less data than -- from Saphnelo and from Roche from the Phase II, you're already into Phase III. Should we think about getting more Phase II this year or when are you planning to give more?
再補充一下 IL-33:看起來即使醫師看到的資料也比——來自 Saphnelo 以及 Roche 的第二期資料——還少,但你們已經進入第三期。我們是否應該期待今年會有更多第二期資料,或你們打算何時提供更多?
Susan Mary Galbraith - EVP of Oncology Research & Development
Susan Mary Galbraith - EVP of Oncology Research & Development
Yes, as you know we're so encourage by our data. We moved right to Phase III in that program and we'll look forward to sharing our Phase II data as it becomes available in our coming medical conference.
是的,如你所知,我們對我們的數據非常受到鼓舞。我們在該計畫中直接推進到第三期,並期待在接下來的醫學會議上,隨著第二期資料可用時與大家分享。
Pascal Soriot - CEO & Executive Director
Pascal Soriot - CEO & Executive Director
So I've got two big ones ongoing. One is, the [INTL-33]. So in acute respiratory (inaudible) and hopefully we will see data after the next season. So somewhere in the next year. And if at all still fingers crossed, it will be the first than anti-IL33 in a complete new segment where there's a very big unmet medical need. The second one clearly our Phase III trial in the COPD space. We've added an additional arm, a high dose and that trial is ongoing and we'll read out in the next 2 years.
我目前有兩個大的項目在進行中。第一個是 [INTL-33]。用於急性呼吸道(聽不清)方面,希望我們能在下一個季節之後看到數據,也就是大約在明年某個時點。如果一切順利、仍然祈禱中,這將會是第一個抗 IL-33,進入一個全新的領域,而那裡有非常大的未被滿足醫療需求。第二個很明確是我們在 COPD 領域的第三期試驗。我們新增了一個額外的組別——高劑量——該試驗正在進行中,並將在未來兩年內讀出結果。
Maybe we take the last question. Is that okay, Andy? So Gonzalo -- question on Gonzalo, at ABG.
也許我們來回答最後一個問題。可以嗎,Andy?那麼 Gonzalo——ABG 的 Gonzalo 的問題。
Gonzalo Artiach Castañón - Research Analyst
Gonzalo Artiach Castañón - Research Analyst
Can you hear me?
你聽得到我嗎?
Pascal Soriot - CEO & Executive Director
Pascal Soriot - CEO & Executive Director
Yes.
聽得到。
Gonzalo Artiach Castañón - Research Analyst
Gonzalo Artiach Castañón - Research Analyst
Gonzalo from ABG Sundal Collier. I have a couple of questions. The first one is on Airsupra. It follows the previous question from the audience. And how big is the expected sales force and commercial team for Airsupra? And what is the current level of awareness of this drug from doctors today? Also in '23, you have been preparing for the launch of the drug. So what is the biggest challenge based on your experience through the year to penetrate the market that one could expect it to be quite conservative?
我是 ABG Sundal Collier 的 Gonzalo。我有幾個問題。第一個是關於 Airsupra,延續前面觀眾的問題。Airsupra 預期的銷售人力與商業團隊規模有多大?目前醫師對這個藥的認知程度如何?另外在 2023 年,你們一直在為上市做準備。那麼根據你們這一年來的經驗,要打入一個可能相當保守的市場,最大的挑戰是什麼?
And the second question is on Tagrisso. It seems from your report today that the demand in China had some issues with the hospital ordering dynamics. So could you give us some color on that? And how much is expected to affect 2024? And the same for the Australian government rebates looking also into '24 and beyond?
第二個問題是關於 Tagrisso。從你們今天的報告看起來,中國的需求在醫院採購訂單的動態上出現了一些問題。你們能否補充一些背景?預期會對 2024 年造成多大影響?另外,澳洲政府的補助回扣也是同樣問題,放眼 2024 年及之後會如何?
Ruud Dobber - Executive Vice-President of BioPharmaceuticals Business Unit
Ruud Dobber - Executive Vice-President of BioPharmaceuticals Business Unit
Let me try to answer all the questions in a concise way. First of all, the field force, I'm not going to let's say, give you complete numbers, but it's a very substantial field for us. It's substantial for 2 reasons. We're detailing on the allergists as well as pulmonologists as well as we are detailing on a very large number of primary care physicians. Now the good news is that field force is a shared field force with Breztri. So we try to be very economically savvy in order to make sure that we're not going over the top.
我試著用精簡的方式回答所有問題。首先,關於外勤團隊(field force),我不打算給你完整的數字,但對我們而言這是一支規模相當可觀的團隊。之所以可觀有兩個原因:我們會向過敏專科醫師以及胸腔科醫師進行推廣,同時也會向非常大量的基層照護醫師進行推廣。好消息是,這支外勤團隊與 Breztri 是共享的。因此我們努力在經濟效率上精打細算,確保不會做得過頭。
The awareness, we have used 2023 to create a very substantial amount of awareness, the awareness is over 80% at the level of both the allergists and pulmonologists and especially allergists are the first prescribers. We started in a soft way in the last quarter. And last quarter, we had already 5,000 trialists, especially at the specialist level for Airsupra. Once again, the biggest challenge and that's the last question you were asking, what is not the headwind, but what is the biggest challenge?
關於認知度,我們利用 2023 年建立了非常可觀的認知度;在過敏專科與胸腔科層級的認知度已超過 80%,而且尤其是過敏專科醫師是第一批開立處方者。我們在上一季以較溫和的方式啟動;而在上一季,Airsupra 已經有 5,000 名試用者(trialists),特別是在專科層級。再一次,你問的最後一個問題是,最大的挑戰是什麼——不是逆風,而是最大的挑戰是什麼?
The biggest challenge is we are very happy that the 3 large commercial PBMs have now listed Airsupra but there are multiple down streams, PBMs, and we still need to gain access there. There's nothing specific to Airsupra. It's just a fact of life of the U.S. environment. So we are working very diligently with our market access teams to -- or in order to create that access. And equally, we're going to bid for Part D in the course of this year as well.
最大的挑戰是:我們很高興美國三大商業 PBM 現在都已將 Airsupra 納入名單,但下游還有許多 PBM,我們仍需要在那裡取得給付准入。這並非 Airsupra 特有的問題,只是美國環境的常態。因此我們正與市場准入團隊非常努力地合作——以建立這些准入。同時,我們也會在今年內針對 Part D 進行投標。
Pascal Soriot - CEO & Executive Director
Pascal Soriot - CEO & Executive Director
Dave, Tagrisso.
Dave,Tagrisso。
David Fredrickson - Executive Vice-President of Oncology Business Unit
David Fredrickson - Executive Vice-President of Oncology Business Unit
Yes. So on Tagrisso within China, the fourth quarter hospital ordering dynamics we've seen for the last several years, and it just really has to do with hospitals managing their budgets as they come to the end of the calendar year, which is also the fiscal year. So it doesn't, for me, carry any weight into outlook for 2024. In fact, as I think about how we enter into 2024. Certainly, we continue to face competition, but where we don't face nearly as much competition is in the adjuvant setting.
是的。所以就中國境內的 Tagrisso 而言,我們在過去幾年看到的第四季醫院採購動態,其實主要與醫院在接近曆年年底(同時也是會計年度年底)時管理預算有關。因此,對我來說,這並不會對 2024 年的展望造成任何影響。事實上,當我思考我們如何進入 2024 年時,當然我們仍會面臨競爭,但在我們競爭壓力沒有那麼大的領域,是在輔助治療(adjuvant)情境。
I think it's important to remind that there's a sizable eGFR population within China. 30% to 40%. Also thoracic surgeons do have the ability to prescribe systemic therapies.
我認為重要的是要提醒大家,中國境內有相當可觀的 eGFR 人群,約 30% 到 40%。另外,胸腔外科醫師也有能力開立全身性治療。
So therefore, there's a relatively high adjuvant treatment rate, and we had ADAURA added into the NRDL with no discount. So I think that we come into the year with an opportunity to see growth in these really real demand side of things. And there are many fewer competitors that are playing within that adjuvant space. And our data, I think, stands as being the most impressive there.
因此,輔助治療的治療率相對較高,而且我們已將 ADAURA 納入 NRDL,且沒有折扣。所以我認為,我們在今年一開始就有機會在真正的需求端看到成長。而在那個輔助治療領域參與競爭的對手少得多。我認為我們的數據在那裡仍是最令人印象深刻的。
The Australia rebate reclassification is almost a direct offset between what you see on the Zoladex established Rest of World Beat and the Tagrisso Rest of World Beat, it's a -- mostly a onetime event. And I'd say mostly just because there's some carry on through the year, but I don't anticipate talking about it ever again.
澳洲回扣(rebate)重新分類,幾乎是你在 Zoladex 既有的「世界其他地區」超預期表現(Beat)與 Tagrisso「世界其他地區」超預期表現之間的直接對沖;這——大多是一個一次性事件。我說「大多」是因為全年仍會有一些延續效應,但我不預期之後還需要再談這件事。
Pascal Soriot - CEO & Executive Director
Pascal Soriot - CEO & Executive Director
Thank you, Dave. So thank you so much for your interest and your great questions. Maybe a few messages to close this meeting. .
謝謝你,Dave。也非常感謝各位的關注與精彩提問。最後用幾個重點訊息來結束今天的會議。.
The first one is just kind of taking into account all the questions asked today. First one is product sales in 2024. We will still have very strong product sales and the product sales will grow. I mean the growth of product sales in -- is coherent with the guidance we gave for top line revenue. So the clear message is, we are not dependent on collaboration revenue to grow in 2024. Our portfolio is doing very well, and all our geographies are doing very, very well.
第一點是,綜合今天大家提出的所有問題。第一個訊息是 2024 年的產品銷售。我們仍將維持非常強勁的產品銷售,而且產品銷售將會成長。我的意思是,產品銷售的成長——與我們對營收(top line revenue)所給出的指引是一致的。所以清楚的訊息是:我們在 2024 年的成長不依賴合作收入(collaboration revenue)。我們的產品組合表現非常好,而且我們所有地區的表現都非常、非常好。
The second message is we are committed to this midterm operating margin, and it is, of course, challenging because as you've said, we have a very big portfolio and we have to invest in this growth, but we will get there. We are committed to this, and we are working towards this, making good progress. You saw the margin expansion in one of the slides, and we'll continue in that direction.
第二個訊息是,我們致力於達成這個中期營業利益率目標。當然這具有挑戰性,因為如你所說,我們的產品組合非常龐大,而我們必須投資以支持這個成長,但我們會達成。我們對此承諾不變,並正朝此方向努力,且進展良好。你們在其中一張投影片中看到利益率擴張,我們會持續朝那個方向前進。
The third message maybe is, we believe we can manage through the Part D reform, and I mentioned it because I know some people have speculated this is going to be a big problem. It is a small headwinds. I mean, headwinds, we have headwinds constantly in one market or another, one product or another. The beauty of our pipeline and our footprint geographically is when 1 product face a headwind and other product picks up, remember, we have 13 products that are blockbuster status today. And 1 geography is struggling a bit another 1 is doing better, and that's really the model as we have it. But overall, Part D and we spent a lot of time, our teams have spent a lot of time working on modeling this.
第三個訊息可能是,我們相信可以因應 Part D 改革,我之所以提到,是因為我知道有些人推測這會成為一個大問題。它是一個小幅逆風。我的意思是,逆風我們一直都會遇到——在某個市場或另一個市場、某個產品或另一個產品。我們的研發管線與全球布局的優勢在於:當一個產品遇到逆風,另一個產品就會補上;請記得,我們目前有 13 個產品達到重磅藥(blockbuster)等級。而當一個地區稍微承壓,另一個地區表現更好——這就是我們的模式。整體而言,針對 Part D,我們花了很多時間,我們的團隊也花了很多時間進行建模分析。
The incremental rebates that we will have to deal with is, first of all, in part compensated by the reduction of free goods, which is substantial for some of our oncology medicines. And overall, the net effect is certainly a negative, but it's really totally manageable in the context of our total global sales and the growth rate we are experiencing.
我們必須面對的新增回扣(incremental rebates),首先會部分被「免費供藥」(free goods)減少所抵銷,而這對我們某些腫瘤藥物而言幅度相當可觀。整體來看,淨影響確實是負面的,但放在我們全球總銷售額以及我們目前的成長率背景下,這是完全可控、可管理的。
And finally, but importantly, we are absolutely confident we can deliver a very strong long-term growth. And that's really what we want to show you and hopefully convince you at this R&D day, and I hope many of you will join us in the beautiful DISC, where we have tremendously talented teams that are doing a great job.
最後但同樣重要的是,我們完全有信心能夠實現非常強勁的長期成長。這正是我們想在這次研發日向各位展示、並希望能說服各位的重點;也希望你們當中有許多人能加入我們,在美麗的 DISC,我們有極具才華的團隊,正在做出非常出色的工作。
We have today a huge number of collaborations in the Cambridge area, and this is really leading to very good productivity from our R&D efforts. With this, thank you very much. And again, thanks for your great questions.
我們目前在劍橋地區有大量合作案,這確實正帶動我們研發工作的高生產力。就此,再次非常感謝。也再次感謝各位精彩的提問。